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tumor elimination, equilibrium, and escape. This “Triple E Hypothesis” reflects host-tumor interactions in a
subset of human cancers that have responded well to cancer immunotherapy, including melanoma, small
cell lung carcinoma, and bladder carcinoma; yet, many tumors remain refractory to such interventions.
These clinical failures suggest that immunosurveillance in other cancers manifests with a fundamentally
different biology than previously described.
Here, using a genetic mouse model of spontaneous pancreatic carcinoma that features an
immunosuppressive microenvironment and few non-synonymous mutations, we report that the natural
history of such cancers is T cell-independent. Furthermore, tumor escape from T cell surveillance is not
required for cancer progression, as tumor cells arising in T cell-depleted genetic mice grow unchecked in
immune-competent hosts upon implantation. Checkpoint blockade with CTLA-4 and PD-1 antibodies does
not expose mutant epitopes strong enough to elicit therapeutic responses; combined with whole exome
sequencing of PDA-derived murine cell lines, these findings confirm that that PDA does not harbor a
mutational burden commensurate with the current hypothesis of immunosurveillance. However, ectopic
expression of a neo-antigen in PDA tumor cells is sufficient to restore immunosurveillance, override its
immunosuppressive microenvironment, and establish T cell memory against “quiescent” endogenous
antigens. Thus, cardinal features of tumor immunosurveillance are elicited by an antigen of sufficient
strength irrespective of microenvironmental immunosuppression. The finding that antigen strength itself
is a critical determinant of cancer immunosurveillance informs future clinical approaches for the majority
of human tumors that are “immunologically cold” and refractory to current immunotherapies.
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ABSTRACT

T CELL IMMUNOSURVEILLANCE IN PANCREATIC DUCTAL
ADENOCARCINOMA

Rebecca A. Evans

Robert H. Vonderheide

The prevailing theory of cancer immune surveillance, as understood from carcinogendriven mouse models of highly mutated tumors, states that T cell-mediated immune
pressure drives a continuum of tumor elimination, equilibrium, and escape. This “Triple
E Hypothesis” reflects host-tumor interactions in a subset of human cancers that have
responded well to cancer immunotherapy, including melanoma, small cell lung
carcinoma, and bladder carcinoma; yet, many tumors remain refractory to such
interventions. These clinical failures suggest that immunosurveillance in other cancers
manifests with a fundamentally different biology than previously described.
Here, using a genetic mouse model of spontaneous pancreatic carcinoma that
features an immunosuppressive microenvironment and few non-synonymous mutations,
we report that the natural history of such cancers is T cell-independent. Furthermore,
tumor escape from T cell surveillance is not required for cancer progression, as tumor
cells arising in T cell-depleted genetic mice grow unchecked in immune-competent hosts
upon implantation. Checkpoint blockade with CTLA-4 and PD-1 antibodies does not
expose mutant epitopes strong enough to elicit therapeutic responses; combined with
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whole exome sequencing of PDA-derived murine cell lines, these findings confirm that
that PDA does not harbor a mutational burden commensurate with the current hypothesis
of immunosurveillance. However, ectopic expression of a neo-antigen in PDA tumor
cells is sufficient to restore immunosurveillance, override its immunosuppressive
microenvironment, and establish T cell memory against “quiescent” endogenous
antigens. Thus, cardinal features of tumor immunosurveillance are elicited by an antigen
of sufficient strength irrespective of microenvironmental immunosuppression. The
finding that antigen strength itself is a critical determinant of cancer immunosurveillance
informs future clinical approaches for the majority of human tumors that are
“immunologically cold” and refractory to current immunotherapies.

iv

TABLE OF CONTENTS

Acknowledgements………………………………………………………………….....p.ii
Abstract………………………………………………………………………………..p.iii
List of Illustrations ………….………………………………………………………..p.vi
Manuscripts………………………………………………………………………….....p.x
Chapter One: Introduction…………..………………………………………………...............p. 1

Chapter Two: Materials and Methods……………….………………………………p. 29
Chapter Three: The natural history and progression of PDA are independent of T cell
immunosurveillance……………………………………………………………...........p. 38
Chapter Four: Neo-antigens override the tumor microenvironment and dictate immune
surveillance in cancer………………………………………………………………....p. 68
Chapter Five: Discussion and Future Directions……………………………….........p. 95
Chapter Six: References………………………………………………………….....p. 105

v

LIST OF ILLUSTRATIONS

Figure 1. Intratumoral T cell infiltration in Gem/CD40-treated KPC mice is dependent
upon ablation of macrophages………………………………………………………...p. 28
Figure 2. Human PDA does not express high levels of CD8 or markers of cytolytic
activity………………………………………………………………………………...p. 52
Figure 3. Experimental design of KPC survival studies……………………………..p. 53
Figure 4. Validation of T cell depletion by antibodies……………………………....p. 54
Figure 5. Time to diagnosis and overall survival of KPC mice are independent of T
cells……………………………………………………………………………………p. 55
Figure 6.

Pancreatic tumors of immune-competent and T cell-depleted KPC mice

demonstrate similar histology………………………………………………………....p. 56
Figure 7.

Pancreatic tumors of immune-competent and T cell-depleted KPC mice

demonstrate similar leukocytic infiltrates…………….……………………………….p. 57
Figure 8. Experimental design for subcutaneous implant studies of syngeneic PDA cell
lines……………………………………………………………………………………p. 58
Figure 9. 4662 KPC cell line grows with the same kinetics upon implantation in
immune-competent or T cell-depleted mice…………………………………………..p. 59
Figure 10. 4662 implanted tumors recapitulate the microenvironment of autochthonous
KPC tumors…………………………………………………………………………...p. 60
Figure 11. Low doses of s.c. 4662 cells do not elicit T cell-mediated tumor regressions or
alter overall survival of recipient mice………………………………………………..p. 61

vi

Figure 12. PD-1 and CTLA-4 blockade do not impact 4662 tumor cell growth or overall
survival of recipient mice……………………………………………………………..p. 62
Figure 13. Validation of T cell depletion in KPC mice used to generate T cell-depleted
tumor cell lines………………………………………………………………………..p. 63
Figure 14. T cell-depleted KPC tumor cell lines grow irrespective of recipient immune
status………………………………………………………………………..................p. 64
Figure 15. Neo-epitopes in KPC-derived tumors are rare…………………………....p. 65
Figure 16. Overall survival and time to diagnosis are increased in CD4-depleted KPC
mice……………………………………………………………………………............p. 66
Figure 17. Genetic deletion of CD4 in iKras mice abrogates PanIN formation following
cerulein-induced pancreatitis………………………………………………………….p. 67
Figure 18. Tdt-Ova 4662 cell line processes and presents SIINFEKL peptide on MHC
class I………………………………………………………………………………….p. 79
Figure 19. Expression of MHC class I and class II on 4662 and V6.Ova tumor cell
lines…………………………………………………………………………………....p. 80
Figure 20. Additional Tdt-Ova expressing 4662 PDA clones………………………..p. 81
Figure 21.

Subcutaneous rejection of V6.Ova 4662 clone is CD8 T cell-

dependent……………………………………………………………………………...p. 82
Figure 22. V6.Ova clone is subcutaneously rejected in immune-competent mice,
resulting in long-term survival………………………………………………………...p. 83
Figure 23. Orthotopic implantation of the 4662 cell line grows out in immune-competent
mice and reproduces classic PDA histology…………………………………………..p. 84

vii

Figure 24. Orthotopic rejection of V6.Ova implants and long-term survival of recipient
mice is CD8 T–cell dependent………………………………………………………...p. 85
Figure 25. Summary of orthotopic and subcutaneous implant studies……………….p. 86
Figure 26. Re-challenge with parental 4662 cells results in T cell-dependent tumor
regressions and delayed tumor outgrowth…………………………………………….p. 87
Figure 27. Experimental design of competition assay between V6.Ova cells and
negatively sorted (OvaNeg) cells……………………………………………………...p. 88
Figure 28. Mixed implants of V6.Ova and OvaNeg cells grow in immune-competent
recipients with kinetics proportional to the admixture ratio…………………………..p. 89
Figure 29. Survival of mice implanted with mixtures of V6.Ova and OvaNeg cells is
dependent upon the admixture ratio………………………………..………………....p. 90
Figure 30. Ova-specific T cells are highly enriched in the tumors of mice implanted with
80% V6.Ova…………………………………………………………………………..p. 91
Figure 31. Intratumoral CD8+ T cells in 80% V6.Ova implants are highly functional and
proliferative……………………………………………………………………………p. 92
Figure 32. Loss of Td-tomato expression in V6.Ova implants is abrogated by CD8depletion……………………………………………………………………………....p. 93
Figure 33. Tumor histology of 80% V6.Ova implants resembles parental 4662
implants……………………………………………………………………………….p. 94
Figure 34. Revised model of tumor immunosurveillance…………………………...p. 102

viii

Figure 35. Comparison of immunoediting in the MCA and KPC models of
tumorigenesis………………………………………………………………………...p. 103
Figure 36. 4662 tumor lysate fails to induce a vaccine effect in tumor-bearing KPC
mice…………………………………………………………………………………..p. 104

ix

MANUSCRIPTS
The following manuscripts are discussed in this thesis:
Evans, R.A., Diamond, M.S., Rech, A.J., Chao, T., Richardson, M.W., Lin, J.H., Bajor,
D.L., Byrne, K.T., Stanger, B.Z., Riley, J.L., Markosyan, N., Winograd, R., and
Vonderheide, R.H. (2015). Neo-antigen overrides tumor microenvironment in
determining cancer immunosurveillance.
Winograd, R., Byrne, K.T., Evans, R.A., Odorizzi, P.M., Meyer, A.R.L., Bajor, D.L.,
Clendenin, C., Stanger, B.Z., Furth, E.E., Wherry, E.J., and Vonderheide, R.H.
(2015). Induction of T cell immunity overcomes complete resistance to PD-1 and
CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer
Immunol Res. 3, 399-411.
Beatty, G.L., Winograd, R., Evans, R.A., Long, K.B., Luque, S.L., Lee, J.W., Clendenin,
C., Gladney, W.L., Knoblock, D.M., Guirnalda, P.D., and Vonderheide, R.H.
(2015). Exclusion of T Cells From Pancreatic Carcinomas in Mice is Regulated
by Ly6C(low) F4/80(+) Extratumoral Macrophages. Gastroenterology, 149, 20110.
Zhang Y., Yan W., Mathew E., Bednar F., Wan S., Collins M.A., Evans R.A., Welling
T.H., Vonderheide R.H., Pasca di Magliano M. (2014). CD4+ lymphocyte
ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res. 2, 42335.

x

Vonderheide, R.H., Bajor, D.L., Winograd, R., Evans, R.A., Bayne, L.J., and Beatty,
G.L. (2013). CD40 immunotherapy for pancreatic cancer. Cancer Immunol.
Immunother. 62, 949-54
Manuscripts not discussed in this thesis:
Markosyan N., Chen E.P., Evans R.A., Ndong V., Vonderheide R.H., Smyth EM.
(2013). Mammary Carcinoma Cell Derived Cyclooxygenase 2 suppresses Tumor
Immune Surveillance by Enhancing Intratumoral Immune Checkpoint Activity. Breast
Cancer Res. 15, R75

xi

CHAPTER 1 – Introduction

Cancer immune surveillance
Anti-tumor immunity is now widely acknowledged as a significant impediment to
cancer formation, akin to an extrinsic tumor suppressor system; currently, immune
evasion is defined in the field as an “emerging hallmark” of cancer progression (Hanahan
and Weinberg, 2011). For decades, however, the field of tumor immunology was
tangential to cancer biology despite the supposition that immunity might target
malignancies with the same potency observed against bacteria, viruses, and parasites.
The earliest scientific foray into tumor immunology harnessed the known antibacterial
function of the immune system in the hands of Dr. William Coley, who observed a
remarkable case of recurrent sarcoma that was eradicated upon accidental contraction of
erysipelas (Coley, 1891). In a series of trials in patients with recurrent and inoperable
sarcomas, Coley intentionally inoculated the patients’ tumors with various strains of
erysipelas; in a number of cases, notably those where patients suffered a full onset of
erysipelas infection, the tumors either shrank or dissolved completely. Thus, the field of
tumor immunology in its nascent form was born in 1891, and “Coley’s toxins” have since
been described as the first clinical trial in this field.
In 1909, Paul Ehrlich inferred from these clinical observations that the immune
system might function as a sentinel-like presence against tumor formation, and only in its
occasional failures would tumors become clinically evident (Dunn et al., 2002). A more
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formal hypothesis was stated by Burnet and Thomas in 1957, where the term “immune
surveillance” was first coined to describe the immune system’s putative protective role
against cancer development. Their hypothesis incorporated the likely genetic basis for
immune recognition of these tumors, stating “inheritable genetic changes must be
common in somatic cells and a proportion of these changes will represent a step towards
malignancy” and that such cells have “new antigenic potentialities” (Burnet, 1957, 1964;
Burnet, 1970). This postulation was unfortunately confounded by mounting evidence
that tumor engraftment and rejection studies in mice merely represented an allograft
rejection, not true tumor surveillance against tumor antigens (Billingham et al., 1956).
Further studies would clearly require syngeneic hosts for any conclusive answers.
The first rigorous scientific assessments of immunosurveillance involved various
methods of inducing immune incompetence in mice followed by observation for
increased susceptibility to tumor formation (Grant and Miller, 1965; Balner and Dersjant,
1966; Burstein and Law, 1971; Trutin-Ostovic et al., 1986). Not surprisingly, an increase
in virally-induced tumors and lymphomas was the result of this early work; in mice
subjected to thymectomy or pharmacological means of immune suppression, this was
primarily attributed to the well-known function of the immune system to protect against
viruses that are potentially transformative. In the instance of increased lymphomas, this
was attributed to chronic inflammation that was a byproduct of bacterial and/or viral
susceptibility. The work was otherwise inconclusive regarding carcinogen-induced
cancers and the development of spontaneous non-viral tumors; if anything, these studies
suggested no effect by the immune system on tumor development.
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The advent of genetic models of immune incompetence, namely the athymic nude
mouse, instilled new hope for conclusive evidence of an anti-tumor surveillance function
for the immune system. In the seminal studies performed by Stutman et al., the theory of
immunosurveillance seemed to be definitively discredited; athymic nude mice did not
demonstrate a decreased latency in tumor onset or increased incidence post-injection of
methylcholanthrene, despite an inability to reject allografts (Stutman, 1974, 1979b, a).
The work by Stutman and colleagues led to the temporary dissolution of the
immunosurveillance hypothesis. Later work, however, revealed key limitations in the
nude mouse as a model of immunodeficiency; these mice were shown to harbor
detectable levels of αβ T cells in addition to extra-thymic production of γδ T cells
(Ikehara et al., 1984; Maleckar and Sherman, 1987). NK cells are also known to be intact
in this model, and their contribution to surveillance was not assessed in the Stutman
study. Moreover, the CBA/H background for the nude mice used by Stutman et al is now
known to have hyper-transformative properties due to a particular enzyme involved in
methylcholanthrene biotransformation to the carcinogenic form (Dunn et al., 2002).
The supposedly defunct immunosurveillance hypothesis experienced a revival
with the discovery of carcinogenic susceptibility in IFNγ and perforin-deficient mice,
suggestive of two immunological pathways involved in surveillance (Dighe et al., 1994;
Street et al., 2001). In a series of landmark studies by Schreiber and colleagues
beginning in 2001, the immunosurveillance hypothesis was virtually resurrected and
redefined in a new context: the hypothesis of immunoediting. In the first of these seminal
studies, Schreiber and colleagues induced tumor formation by injection of
methylcholanthrene into the flank of immunocompetent or RAG2-null mice that lack
3

mature T and B cells (Shankaran et al., 2001). Immunodeficiency was shown to augment
tumorigenesis in RAG2-null mice, suggesting an elimination phase of
immunosurveillance whereby adaptive immunity can recognize neoplastic cells and
destroy them. This elimination of tumor cells recalled the former suggestion of a sentinel
function by the immune system as stated by Burnet and Thomas. However, the study
revealed new complexity regarding the interplay between the immune system and
tumors; clearly, this was not an “all or nothing” interaction. 40% of tumors derived from
the RAG2-/- mice were rejected in immune-competent hosts following transplantation,
whereas tumors derived from wild-type mice grew without any seeming protection from
the immune system. These findings suggested the adaptive immune system’s potential
for “sculpting” a tumor’s behavior; these tumors have to escape immune pressure in
order to progress, and this is accomplished by selection of stochastic clones that are not
susceptible to T cell recognition or killing. Additionally, they crossed the RAG2-/mouse to STAT1-/- mice (RkSk mice) to assess the overlap between lymphocytic control
and IFNγ-mediated immunity, known to function through STAT1 signaling (Bach et al.,
1997). Only a marginal increase in tumor incidence was observed with administration of
methylcholanthrene in the double knockout compared to either individual knockout
model, indicative of significant overlap between these two anti-tumor systems.
A third state of host-tumor interactions was defined in a subsequent study,
referred to as “equilibrium” (Koebel et al., 2007). Schreiber and colleagues subjected
C57BL/6 wildtype mice to low doses of methylcholanthrene, and monitored any tumor
development for 200 days. Those mice that developed progressive tumors were removed
from the study, whereas those with stable tumors (or lack thereof) were further subjected
4

to a T-cell depleting antibody cocktail or an IgG isotype control. Those mice in the
immune-compromised cohort developed rapid outgrowth of tumors in comparison to the
control cohort. Delayed de novo onset of tumors was ruled out by comparing the time to
tumor formation in RAG2-/- mice post-MCA with time to formation in wild-type mice
subjected to T cell depletion at day 200; the rapidity of measurable tumor growth after
day 200 in T cell-depleted mice suggested outgrowth of occult tumor cells rather than the
de novo formation seen in RAG2-/- mice. Thus, Schreiber and colleagues hypothesized
that fully transformed cells were being restrained in a static state, and were released to the
escape phase upon interference with T cell-mediated immunity. This study led to the
current prevailing theory of immunosurveillance, known as the “Triple E hypothesis.”
This theory encompassed not only the Burnet and Thomas concept of elimination, but
also incorporated equilibrium and escape phases as extensions of their original
hypothesis for a more comprehensive description of host-tumor interactions.

The first E: Elimination
As first suggested by Paul Ehrlich and confirmed by Schreiber, clinically apparent
cancers in immune competent hosts represent a mere fraction of the transformed cells that
are eradicated throughout an individual’s lifetime, due to complete control in a majority
of instances and truncation of the full immunoediting process (Dunn et al., 2004). Thus,
the immune system represents an extrinsic line of defense when the cell intrinsic
mechanisms of DNA damage repair and apoptosis have failed. This eradication of
nascent, transformed cells by the coordinated response of innate and adaptive immunity
5

is indeed demonstrated in numerous clinical examples. The presence of CD3+ tumorinfiltrating lymphocytes (TILs) has been correlated with better prognosis for both ovarian
and colorectal cancer, among many others (Zhang et al., 2003; Galon et al., 2006). The
increased incidence of cancer in immunodeficient human populations corroborates this
protective role (Frisch et al., 2001; MacKie et al., 2003). Therefore, clinical evidence
supports a model whereby the immune system can eradicate cancerous cells, which may
be an ongoing process even in cancers that have continued to progress.
The mechanisms by which the immune system recognizes and destroys
transformed cells are still being elucidated, although significant strides have been made
in understanding this complex process. Innate immunity and adaptive immunity coalesce
to provide the integrated control required for recognition and eradication of diseased
cells. Integral to this process appears to be the production of the cytokine IFNγ, as
demonstrated by the early knockout studies (Dighe et al., 1994; Shankaran et al., 2001),
but this cascade requires numerous preliminary steps. Cancerous cells instigate a local
inflammatory reaction through the production of various “danger signals,” such as the
secretion of uric acid (Shi et al., 2003), or by triggering inflammatory signaling pathways
through heat shock proteins or extracellular matrix products such as hyaluronic acid and
heparan sulfate (Dunn et al., 2004). Transformed cells experience metabolic stress by
virtue of their hyperproliferative state, leading to the upregulation of certain MHC-Irelated molecules on the surface of these cells, notably MIC-A, MIC-B, and Rae1 (Groh
et al., 1999; Diefenbach et al., 2001). These molecules function as ligands for the
activating NK cell receptor, NKG2D, which stimulates the PI 3-kinase pathway and
ultimately generates IFNγ production by the cell (Khong and Restifo, 2002).
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Innate-like lymphocytes, known as γδ T cells, likewise induce IFNγ at early
timepoints in response to NKG2D ligation or direct recognition of antigens (Girardi et al.,
2001; Gao et al., 2003). Not only are these cells shown to be recruited as early as day 3
following MCA induction of sarcomas, but moreover bone marrow chimeras where mice
were reconstituted with IFNγ-deficient γδ cells and functional αβ cells led to an increased
susceptibility to MCA-induced carcinogenesis and B16 melanoma implants (Gao et al.,
2003). NKT cells similarly demonstrate robust and early production of IFNγ; their
invariant receptor recognizes aberrant glycolipids.
The overarching effect of these early responders is to secrete a critical mass of the
IFNγ cytokine at the site of tumorigenesis, which provides the essential link between
innate and adaptive anti-tumor immunity (Dighe et al., 1994; Bromberg et al., 1996;
Kumar et al., 1997; Kaplan et al., 1998; Street et al., 2002). The effects of IFNγ are
manifold; in addition to recruiting antigen presenting cells (APCs) such as macrophages
and dendritic cells, IFNγ itself can induce a degree of tumor cell death directly or through
inhibition of neovascularization and subsequent ischemic necrosis. Such immunogenic
cell death releases tumor-associated antigens, in the context of pro-inflammatory
“danger-associated molecular patterns” (DAMPs), which can be taken up by the APCs
through phagocytosis or macropinocytosis (Zitvogel et al., 2010). These cells traffic to
local lymph nodes, where they encounter their cognate CD4+ (helper) and CD8+
(effector) T cells. Activated helper CD4+ T cells “license” APC’s via ligation of CD40,
which upregulates various costimulatory molecules on the surface of the APC, such that
cross-presentation of antigen on MHC class I (“signal 1”) in the context of co-stimulation
(“signal 2”) activates the cognate CD8+ T cell receptor. Subsequently, these
7

lymphocytes are induced to proliferate and mature, resulting in an effector phenotype
capable of trafficking to the site of tumorigenesis.
Once the adaptive immune response has been engaged in this manner, innate and
adaptive immunity synergize to eliminate the tumor cells. A predominant component of
effector function in CD8+ T cells is perforin, a cytotoxic protein secreted via
degranulation (van den Broek et al., 1996; Smyth et al., 2000). Experimentally, mice
lacking perforin or IFNγ demonstrated a similar increase in susceptibility to
carcinogenesis that was not significantly enhanced in the double knockout, suggesting
significant overlap of these two pathways (Street et al., 2001). Serine proteases called
granzymes are also present in these granules; the two proteins function concomitantly in
a calcium-dependent manner to kill the target cell. When the peptide-MHC class I
complex is bound by the cognate TCR of an activated T cell, degranulation occurs.
Perforin forms a pore in the target cell membrane, through which the granzyme proteins
enter the cell and initiate cleavage of caspase 3, triggering a cascade of events that results
in DNA fragmentation and cell death (Khong and Restifo, 2002). This granular release is
highly polarized at the immunological synapse, allowing for selective killing of the target
cell. Meanwhile, an activated CD8 T cell will provide a new source of IFNγ, which
induces an M-1 (anti-tumor) fate in macrophages (Mills et al., 1992). A tumoricidal
phenotype in peritoneal macrophages has been shown to depend on CD40 ligation and
stimulation by IFNγ, resulting in reduced proliferation of B16 melanoma cells in vitro, as
well as an increase in apoptosis and nitrous oxide production (Buhtoiarov et al., 2005).
In turn, such M1-skewed macrophages enhance the T cell anti-tumor response and create
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a positive feedback loop that integrates both innate and adaptive immunity (Duluc et al.,
2009).
CD4+ T cells have also demonstrated efficacy in the elimination phase, although
they are often considered a secondary means of clearance compared to their CD8+
cytotoxic counterparts. Due to their dependence on MHC class II presentation, CD4 cells
usually cannot recognize tumor cells directly; however, one example of a CD4-mediated
anti-tumor response involves clearance of pre-malignant cells harboring a senescenceassociated secretory phenotype (SASP) (Kang et al., 2011). Thus, cells that would
otherwise remain and ultimately develop into malignancies are eliminated at early stages
due to an aberrant SASP program.

The second E: Equilibrium

The most elusive stage of immunoediting can occur if the elimination process does not
eradicate the tumor, but neither has full escape of immune control been achieved by the
transformed cells – resulting in the covert presence of a sub-clinical tumor.
Hypothetically, this period may be short or protracted depending on the degree of
immune pressure and the opposing ability of the tumor to mutate and adapt. Indeed, this
may be likened to a state of tumor dormancy or latency. Conclusive evidence of this
intermediate “static” state remained underwhelming until an interesting case study
published in the New England Journal of Medicine (MacKie et al., 2003). An organ
9

donor at Glasgow University, who had successfully undergone treatment for melanoma,
died 15 years later of unrelated causes. Two patients received the donated kidneys;
within two years of successful engraftment, however, each recipient developed secondary
melanoma. Immunosuppressive therapy was ceased in both patients, one of whom
succumbed to metastatic melanoma. The other rejected the diseased kidney following
IFNγ treatment, and went on to survive without spread of the disease. This clinical
evidence of an immune-mediated suppression of melanoma in the donor that
subsequently progressed in immune-compromised patients suggests a state of static
dormancy; the melanoma cells were never fully eliminated in the original donor, but they
had been diminished to a state of clinical irrelevance prior to outgrowth in the recipients.
This interesting case study prompted Schreiber and colleagues to interrogate the presence
of such a state in a controlled mouse model, as previously described, and the term
“equilibrium” was coined for this intermediate state (Koebel et al., 2007).
From the initial MCA-induced carcinoma study, it was apparent that equilibrium
was mediated by CD4+ and CD8+ T cells as well as IFNγ. A follow-up study
determined two further immune components critical to this stasis, which help define it as
a discrete (and potentially prolonged) stage in the immunoediting process (Teng et al.,
2012). The MCA model of carcinogenesis was again utilized to assess the interplay
between the heterodimeric cytokines IL-23 and IL-12, which share a p40 subunit. Study
of tumor-free mice 200, 300, or 400 days post-MCA induction revealed that equilibrium
could be markedly prolonged until disruption of immunity with antibodies targeting T
cells and IFNγ. Additionally, neutralizing antibodies targeting IL-23 and IL-12 in MCAtreated, disease-free mice resulted in decreased or increased tumor escape, respectively.
10

Administration of agonistic CD40 antibodies to promote IL-12 production by dendritic
cells confirmed these findings; this treatment conferred a protective effect, as measured
by a decrease in tumor escape upon disruption of T cell immunity. Overall, the data
suggested a role for IL-23 in maintenance of occult tumor cells, whereas IL-12 inhibits
progression to escape. Other cytokines important in elimination were shown to be
irrelevant at this stage, distinguishing it as a unique step in the immunoediting process
with a discrete set of regulating factors (Muller-Hermelink et al., 2008; Kang et al.,
2011).
Equilibrium can also be achieved by simply preventing tumor outgrowth without
actual elimination of tumor cells. As shown using the RIP-TAG mouse, in which Tagdriven carcinoma is specific to all pancreatic islet cells, adoptive transfer of Tag-specific
CD4+ T cells did not cause autoimmune diabetes (Muller-Hermelink et al., 2008). At an
age where untreated RIP-TAG mice typically developed multiple carcinoma lesions with
robust vasculature, the same mice treated with the T-cell therapy had only small,
hypovascular, pre-neoplastic lesions. Using immunohistology to detect αvβ3-expressing
vessels as a measure of angiogenesis, the study concluded that such vessels were rare in
mice given the adoptive transfer procedure. Likewise, proliferation was decreased in the
islet cells of adoptively transferred TAG mice, as determined by BrdU labeling.
Interestingly, arrest was not CD8-dependent in this study, indicating that CD4+ cells may
frequently be involved with the equilibrium state since they only indirectly inhibit tumor
growth rather than directly recognizing and killing MHC class I+ tumor cells. In the
same model, another study demonstrated that Th-1 helper cytokines IFNγ and TNF were
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shown to induce cell cycle arrest in G1/G0; the effect was lost in Tnfr1-null mice
(Braumuller et al., 2013).

The third E: Escape

If tumors escape immune control, they are described as having been “immunoedited” by
their interaction with the immune system. These escaped tumor populations have been
selected for cell-autonomous properties that permit them to grow in the presence of a
functional immune system. Schreiber and colleagues have recently used the MCA mouse
model to describe a principal mechanism of escape: downregulation of a particular
antigenic epitope as determined by exome sequencing of parent lines and escaped
daughter clones (Matsushita et al., 2012). Similarly, downregulation of MHC class I
molecules by tumor cells has been implicated in many instances of immune escape. In a
landmark melanoma study of human biopsy samples, known tumor antigens like Melan
A/MART-1 and tyrosinase were not lost in all cases of progressive melanoma; 9/20
tumors had in fact lost expression of MHC class I, thereby rendering the antigens
invisible to the immune system (Jager et al., 1997). Even within a single individual, a
combination of these escape mechanisms may be seen in recurrent tumors or metastases,
some of which lose antigen expression, while some lesions may lose MHC class I
expression (Khong et al., 2004). Other malfunctions in the antigen processing pathway
are likewise implicated in cancer progression. The peptide transporters, TAP-1 and TAP2, have been downregulated in cases of small lung cell carcinoma, non-small cell lung
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cancer, prostate carcinoma, and renal cell carcinoma (Restifo et al., 1993; Sanda et al.,
1995; Korkolopoulou et al., 1996). IL-10 production by tumor cells has been implicated
in this downregulation, representing an autocrine means of escape.
Cancer cells may also develop mutations that disrupt the apoptotic pathway and
render them resistant to T cell killing. Downregulation of Fas expression may occur
directly, or downstream signaling by cleaved caspase may be disrupted upon upregulation
of cFLIP, a protein that inhibits caspase-8 (Khong and Restifo, 2002). Even perforin and
granzyme B-induced killing can be subverted in the presence of the serine protease
inhibitor PI-9 (Medema et al., 2001). Tumors may also exert negative influences on
otherwise reactive T cells, sometimes directly by death receptor ligation. FAS-L
upregulation on various tumor types has been reported clinically in lung carcinoma,
melanoma, colon carcinoma, and hepatocellular carcinoma (Khong and Restifo, 2002);
presumably, ligation of any FAS+ T cell would be susceptible to apoptosis. Despite this
interesting observation, its implications are still unclear and these data remain mostly
correlative. In other studies, FAS-L expression was not observed at either the mRNA or
protein levels; moreover, in vitro exposure of melanoma cells to FAS+ T cells did not
induce killing (Chappell et al., 1999). A more relevant and likely scenario for apoptosis
of tumor-reactive T cells is the upregulation of FAS-L upon antigen recognition within
the tumor, a phenomenon known as activation-induced cell death (AICD), resulting in
“suicide” of the cell itself or “fratricide” of bystander FAS+ T cells (Zaks et al., 1999).
Each of these examples represents the conventional understanding of immunoediting in
which edited tumors possess direct means of escaping immunity, either by avoiding
recognition or immune-mediated killing.
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Tumors may also indirectly hamper T cell efficacy through manipulating the
tumor microenvironment. As critical regulators of T cell priming, dendritic cells are
frequently co-opted by tumors to disrupt T cell surveillance. IL-10 produced by tumor
cells can inhibit dendritic cell maturation and function, leading to sub-optimal priming
(Rabinovich et al., 2007). Tumor-derived cytokines like TGF-β1 have been shown to
promote dysfunctional antigen presentation via the upregulation of tolerogenic PDL-1 on
dendritic cells (Scarlett et al., 2012).
In numerous cancers, tumor-associated myeloid cells have been extensively
shown to disrupt T cell function through a variety of mechanisms. These cells may
induce T cell apoptosis by secretion of nitric oxide (Rabinovich et al., 2007) or arginase1, which depletes the microenvironment of critical T cell nutrients like L-arginine
(Albina and Henry, 1991; Rodriguez et al., 2004). Tumor-derived GM-CSF has recently
been observed to recruit myeloid-derived suppressor cells (MDSCs) in the setting of
pancreatic ductal adenocarcinoma, resulting in abrogation of perforin-dependent T cell
function (Bayne et al., 2012). The hypoxic microenvironment typical of many solid
tumors can also upregulate HIF-1α in tumor-associated myeloid cells, which induces an
immunosuppressive effect on lymphocytes. In the MMTV-PyMT model of mammary
carcinogenesis, the generation of myeloid HIF-1α-null transgenics slowed tumor
progression in a T cell-dependent manner (Doedens et al., 2010).
Macrophages can likewise be harnessed by tumors; in a process known as
polarization, otherwise anti-tumor “M1” cells are redirected to a tumor-promoting “M2”
fate by a specific cytokine milieu. M1 macrophages arise in the context of an
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environment rich in IFNγ and bacterial products, whereas M2 macrophages develop
under conditions of IL-4, IL-10, and IL-13 (Gabrilovich et al., 2012). In fact, Th2 cells
within the tumor have been shown to be a source of IL-4 and alternative activation of
macrophages; in the MMTV–PyMT model of mammary carcinogenesis, CD4-deficient
mice demonstrated an abundance of type-1 cytokines and decreased M2 markers
(DeNardo et al., 2009). The alternatively activated macrophages demonstrate antiimmune effects similar to their myeloid precursors, as described above. Additionally,
they provide a source of CCL22 to attract another inhibitory population of cells known as
regulatory T cells (Tregs) (Curiel et al., 2004). Tregs, in turn, have been shown to drive
alternative skewing of macrophages by secreting IL-10 and preventing their sensitivity to
LPS (Tiemessen et al., 2007), creating a positive feedback loop whereby various
components of the tumor microenvironment synergize to construct a complex
immunosuppressive network.
Such crosstalk between tumors and the stromal cells has thus been proposed as an
alternative form of immunoediting, whereby the tumor retains its antigenicity and instead
mediates immunosuppression in order to permit outgrowth. Directly or indirectly, escape
mechanisms can permit paradoxical tumor progression within immunocompetent
individuals. Similar to the antibiotic resistance observed in microbial strains, an immune
response that incompletely suppresses tumor growth can inadvertently select for clones
that have escaped this pressure. However, the term “tumor escape” is actually a
misnomer; it implies an active and intentional behavior by tumor cells (Khong and
Restifo, 2002). Rather, failure of T cell immunosurveillance most likely involves a
passive process, whereby tumors evade T cells through inherent genomic instability,
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subsequent heterogeneity, and ultimately natural selection of clones that can survive in a
setting of immune-based pressure.
Although considered the prevailing view of immunosurveillance, the
immunoediting hypothesis has been subject to various criticisms. Blankenstein and
colleagues have proposed that a majority of immunogenic cancers will induce peripheral
T cell tolerance rather than undergo tumor immunoediting; thus, he suggests that the
failure of surveillance may ultimately be T cell intrinsic (Willimsky and Blankenstein,
2005; Willimsky et al., 2008). Another example of T cell dysfunction was suggested in a
study of the gene expression profiles of various metastatic melanoma samples, where a
subset of T cell-rich tumors paradoxically demonstrated increases in inhibitory molecules
like IDO, PD-LI, and CCR4-binding chemokines that cause an influx of Tregs (Spranger
et al., 2013). Interestingly, those tumors that were T cell-poor lacked the expression of
these factors, suggesting a T cell-mediated immunosuppression. This finding was
corroborated in mouse models of B16.SIY melanoma; in CD8-depleted mice,
upregulation of inhibitory molecules failed to occur, and Treg trafficking was greatly
reduced. Proponents of the immunoediting hypothesis, however, might point to the
upregulation of such inhibitory molecules in the presence of T cells as “adaptive immune
resistance” – essentially, a form of tumor escape. This “chicken-egg” question is still
debated within the field of tumor immunology (Tumeh et al., 2014; Winograd et al.,
2015).
Indeed, the constitutive expression of inhibitory molecules on the surface of T
cells, including PD-1 and CTLA-4, can account for failed T cell responses in many
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cancers; although beneficial for preventing auto-immunity and resolving inflammation,
these molecules serve as a double-edged sword in the context of cancer. This counterproductive expression has formed the basis of checkpoint blockade therapy, which has
led to dramatic clinical responses in certain cancers such as melanoma (Tumeh et al.,
2014). Schreiber and colleagues utilized checkpoint inhibitors to prompt inert T cells to
respond to “silent” neo-antigens in a progressor MCA-induced cell line (Gubin et al.,
2014). Following checkpoint blockade of this cell line in host mice, Gubin et al. used
RNA-seq of tumor-infiltrating lymphocytes to reveal that these cells had decreased
markers of exhaustion, such as LAG-3 and TIM3. Without checkpoint intervention,
expression of these molecules was similar to the levels observed during chronic viral
infection. Thus, features inherent to T cell immunobiology – albeit protective of the
organism in other settings – become counter-productive in certain cancers and account
for tumor progression in the absence of tumor-derived “escape” mechanisms.

Pancreatic ductal adenocarcinoma and the KPC model

Pancreatic ductal adenocarcinoma is a notoriously devastating disease. It currently ranks
4th amongst cancer-associated deaths in the United States despite being only the 10th
most-commonly diagnosed cancer, indicative of its highly aggressive nature (Siegel et al.,
2012); however, it is predicted to surpass all but lung carcinoma by the year 2020 in its
lethality (Rahib et al., 2014). Most patients present with a vague array of symptoms,
which may be limited to abdominal pain, nausea and weight loss. Often the results of
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bloodwork are similarly non-specific. A combination of jaundice, dysglycemia, and
pancreatitis is more overtly suggestive of PDA. Regardless of the presenting complaints,
most patients are diagnosed with advanced malignancy; even those few patients deemed
to have resectable tumors usually succumb to metastatic disease, resulting in a 5-year
survival rate of only 6% (Hidalgo, 2010; Siegel et al., 2012).
The treatment options available for PDA are indeed limited and insufficient. The
previous standard-of-care chemotherapy, gemcitabine, extends lifespan by only a few
months beyond palliative care, which remains the ultimate recourse for a majority of
patients with advanced disease (Tempero et al., 2003). A combined chemotherapy
regimen, FOLFIRINOX, was recently demonstrated to increase median overall survival
to 11.1 months in patients with metastatic disease, but toxicity limits its use to candidates
with a good performance status (Conroy et al., 2011). Similarly, the 2013 FDA approval
of Nab-paclitaxel reflects the underwhelming advances in PDA treatment; a phase 3
clinical trial combining Nab-paclitaxel with gemcitabine extended median overall
survival to 8.5 months in patients with metastatic disease, compared to 6.7 months in the
gemcitabine monotherapy cohort (Von Hoff et al., 2013). Such minimal improvements
underscore the need for alternative treatments, especially in light of an aging population
and the striking lethality of this disease. Development of future therapies will require
understanding what drives this uniquely aggressive biology.
Tuveson and colleagues recently developed a genetically engineered mouse
model (GEMM) that will facilitate investigation of such concerns; this model closely
recapitulates the molecular, histopathologic and clinical features of human PDA
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(Hingorani et al., 2005). Human PDA is driven by the cumulative effect of successive
driver and supporting mutations, beginning with a histological precursor known as
pancreatic intraepithelial neoplasia (PanIN) (Hidalgo, 2010). Activation of the mutant
KRAS oncogene is the most notable genetic aberration, occurring in greater than 95% of
patients; this mutation causes a constitutively active GTPase, encouraging cellular
proliferation. Subsequent mutations frequently include inactivation of the tumor
suppressor gene CDKN2A (encoding INK4A), as well as two other tumor suppressor
genes, TP53 and SMAD4 (Hidalgo, 2010). Accordingly, pancreatic cancer in the mouse
model is driven by the targeted expression of activating KrasG12D and dominant negative
Trp53R172H, which are introduced embryonically by Cre-mediated recombination of LSLcassettes in the pancreas, under control of the pancreas-specific promoter Pdx-1. At day
8 of embryonic development, the Pdx-1 promoter becomes active, and subsequent
production of the Cre protein unlocks the transgenes and their production of the mutant
proteins. The resulting “KPC” mouse thus reflects two of the most commonly mutated
alleles in human PDA (Rustgi, 2006). Concomitant expression of these mutations in the
KPC mouse leads to 100% penetrance of a highly invasive, genomically unstable
carcinoma that parallels human PDA at all stages, including the robust desmoplastic
reaction seen by histology (Hingorani et al., 2005).
Desmoplasia within PDA is driven in part by pancreatic stellate cells; in the
context of growth factors, these cells upregulate α-smooth muscle actin and deposit an
abundance of collagen fibers (Hidalgo, 2010). This hallmark reaction has garnered
attention in various studies but remains a controversial topic. Previously, the dense
stroma was shown to physically impede gemcitabine delivery (Olive et al., 2009;
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Provenzano et al., 2012). Disruption of the stroma-promoting Hedgehog signaling
pathway in the KPC model synergized with gemcitabine in a perfusion-dependent
manner. Similarly, depletion of hyaluronic acid increased intratumoral vessel density and
perfusion in this model, facilitating distribution of chemotherapy and improving survival.
More recently, however, two studies challenged this paradigm and demonstrated
that the stromal compartment of PDA may function, at least in part, to limit tumor growth
and invasion. Sonic hedgehog-null mice, when crossed with the KPC model, exhibited a
more undifferentiated, aggressive phenotype and enhanced angiogenesis (Rhim et al.,
2014). In a similar mouse model of PDA, known as the PKT model (Cre-mediated
recombination of floxed TGFβ, in addition to KrasG12D), Ozdemir et al. crossed these
mice with a ganciclovir-sensitive αSMA-tk transgenic mouse to temporally regulate the
levels of SMA+ myofibroblasts (Ozdemir et al., 2014). Depletion of the myofibroblasts
in mice at early or late stages of tumor development decreased overall survival, which
correlated with increased invasiveness and poor cellular differentiation. Thus, the
complexity of the tumor microenvironment in PDA suggests that targeting the stroma
may be more nuanced than initially thought.
The KPC model has been further manipulated by inducing expression of the YFP
protein at the Rosa locus (Rhim et al., 2012). The lineage tracing permitted by this model
has provided new insights into metastasis and epithelial-to-mesenchymal transition
(EMT) in murine PDA. Cells of pancreatic epithelial origin were effectively traced
regardless of their phenotype; surprisingly, these circulating cells were found in
abundance throughout the blood as well as in the liver – a common site of metastasis –
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even at the pre-malignant phase of pancreatic intraepithelial neoplasia (PanIN) in the
pancreas. Contrary to the previous belief that metastasis occurs late in cancer
progression, this study revealed that the lethality of PDA may be associated with early
dissemination of pre-malignant cells.
Another variation of this model allows for the doxycycline-dependent induction
of Kras (or de-induction), permitting temporal as well as spatial control in the expression
of this activating mutation (Ying et al., 2012). This triple transgenic model revealed an
absolute dependence of PDA maintenance upon the Kras mutation, even once PDA has
been established with all the classic stromal features that typically define it. Within 24
hours of doxycycline withdrawal, the stromal elements dissolved, tumor cells regressed,
and FGD-uptake was lost upon PET/CT scanning. Thus, the KPC model and its
subsequent derivatives strongly mimic human PDA and reveal unique features of the
pathobiology of this aggressive disease.
Human PDA has recently been subjected to broad-scale analysis on a genomic
level, revealing further insights into the “mutational landscape” of this disease (Waddell
et al., 2015). In the most recent study, whole genome sequencing of 100 patients’ tumors
reiterated the significance of known driver mutations like Kras, P53, SMAD4 and
CDkN2, as well as a plethora of less frequent contributors. Importantly, the study
accentuated the significance of chromosomal (structural) variations, such as deletion,
rearrangement, amplification, or gene fusions. Certain genetic signatures defined four
subtypes of PDA: stable, scattered, unstable, or locally rearranged. These categories
were then correlated with responsiveness to platinum-based therapy; interestingly, the
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“unstable” genotype was the most responsive. Selective therapeutics based on these
signatures may be on the horizon, although the heterogeneity in these tumors is still a
daunting impediment to therapeutic efficacy. A similar study of Kras-driven lung cancer
revealed that the source of the Kras mutation is important in determining the scope and
type of genomic aberrations (Westcott et al., 2015). Carcinogen-induced Kras expression
by methyl-nitrosourea (MNU) resulted in 192 non-synonymous somatic single-nucleotide
variants, in stark contrast to the 6 induced by genetic induction of Kras. Moreover, the
abnormalities observed in the genetic Kras model validated the findings of the previous
PDA study; a majority harbored structural abnormalities like aneuploidy and copy
number alteration.

PDA and the immune system

The inflammatory infiltrate that co-exists within the PDA fibrous network is intimately
associated with the initiation and progression of this disease, as demonstrated by the
strong correlation between the incidence of chronic pancreatitis and PDA (Chu et al.,
2007). Both PDA and chronic pancreatitis elicit constitutive NF-κB activity, leading to
subsequent production of pro-invasive and pro-angiogenic factors that can contribute to
tumorigenesis and progression (Chu et al., 2007). Likewise, mutant Kras itself has been
shown to be inflammatory. In a mouse model of Kras-driven lung adenocarcinoma, mice
die early from a robust immune infiltrate consisting of macrophages and neutrophils in
the alveolar airspace, rather than from tumor burden itself (Ji et al., 2006).
22

Likewise, Kras establishes a pro-inflammatory microenvironment early in the
development of PDA in KPC mice. Histologic analysis of KPC tumors reveals an
abundance of leukocytes but a scarcity of effector CD8+ cells, even at the pre-invasive
stage of disease known as pancreatic intraepithelial neoplasia (PanIN) (Clark et al., 2007;
Clark et al., 2009). Instead, immunosuppressive populations including tumor-associated
macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells
dominate this leukocytic infiltrate. As described above, each of these populations has
been shown to interfere with T cell function through an assortment of mechanisms that
ultimately disrupt priming, inhibit cytokine secretion by effector T cells, or induce T cell
tolerance and even apoptosis (Rabinovich et al., 2007).
Despite the refractory nature of PDA to chemotherapy, targeting the
immunosuppressive microenvironment has demonstrated some promise in overcoming
this lethal disease. CD40, an activating receptor on antigen presenting cells, can be
ligated with an agonistic antibody to drive T cell priming; initially, our lab hypothesized
that such treatment might enhance T cell-mediated surveillance of PDA in combination
with gemcitabine. Agonistic CD40 antibodies indeed drove tumor regression in both
humans and mice; however, we were surprised to discover that this mechanism was T
cell-independent (Beatty et al., 2011). Agonistic CD40 in fact re-educated macrophages
to become tumoricidal, resulting in macrophage-dependent ablation of the PDA stromal
compartment in mice.
I assisted in a parallel study while a rotating student in the Vonderheide
laboratory, where the function of macrophages in PDA proved more complex than we
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anticipated (Beatty et al., 2015). We initially sought to determine whether
immunosuppression in the KPC model was systemic, and employed a “two tumor” model
to address this question. KPC mice bearing autochthonous pancreatic tumors were
simultaneously implanted with a KPC-derived cell line under the skin, resulting in T celldependent regression of the implanted tumors upon administration of gem/CD40
(“FGK”). This finding indicated that the immunosuppressive effect was
compartmentalized to the pancreas, akin to a site of immune privilege. In surprising
contrast to the prior study, we discovered that a subset of Ly6C(low) macrophages
mediated this local suppression, as their depletion by clodronate-encapsulated liposomes
(CEL) in combination with gem/CD40 therapy was required for CD8+ T cell trafficking
into the pancreas (Fig 1), which coincided with increased levels of T cell-associated
cytokines in the serum. This study highlights the daunting complexity of the tumor
microenvironment in PDA, where innate immune cells demonstrate highly contextualized
roles.
In support of this finding, our lab and colleagues at New York University recently
demonstrated that tumor-derived GM-CSF promotes intratumoral infiltration of myeloid
cells in KPC mice, in which their production of arginase and iNOS can diminish T cell
infiltration, proliferation and IFNγ production (Bayne et al., 2012; Pylayeva-Gupta et al.,
2012). Thus, it appears that PDA is a prime example of how cancers may usurp the
innate compartment of the immune system and harness its ability to regulate T cell
function.
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We more recently demonstrated that T cell-mediated effects can also be induced
in the KPC model through checkpoint blockade of PD-1 and CTLA-4, in combination
with a vaccination cocktail of the CD40 agonist and chemotherapy (Winograd et al.,
2015). Together, these studies reveal the presence of endogenous antigens in PDA; albeit
weak enough to be overpowered by immunosuppressive factors at baseline, these
antigens can elicit a T-cell mediated response when immune therapies enhance T cell
function or disrupt the tumor microenvironment.
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Goals and key findings of this thesis project

PDA is lethal in 100% of untreated KPC mice, reflective of the dismal survival statistics
in humans. This implies an ultimate failure of T cell immunosurveillance, but previous
studies of PDA have not interrogated the extent to which T cell function is abrogated, or
whether immunosuppression permits wholesale exclusion of T cell immunity throughout
tumor inception and invasion. Addressing this gap in our understanding of the
immunobiology of PDA is critical for directing future approaches to immunotherapy.
I hypothesized that the ultimate failure of T cell immunosurveillance in PDA was
not due to classical immunoediting and escape; rather, I believed that the
immunosuppressive microenvironment would exclude surveillance at the outset,
permitting paradoxical outgrowth of tumors with antigenic profiles. I therefore postulated
that the tumor microenvironment principally dictates the course of this disease.
To begin interrogating this hypothesis, I depleted juvenile KPC mice of their
various T cell subsets to determine their effect on the overall outcome of this PDA. As I
anticipated, T cells did not alter the course of tumor progression in KPC mice. However,
upon implantation of the 4662 KPC cell line in an immune-competent host, tumors were
not rejected and outgrowth was not delayed. Moreover, generating cell lines from T-cell
depleted KPC mice did not render them susceptible to rejection. I then considered the
possibility that KPC tumors are actually immunologically “cold,” contrary to my original
hypothesis, and that immunosuppression may not dictate the outcome of this disease.
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Whole exome sequencing of the KPC cell lines revealed that these tumors,
regardless of the immune competence of the donor, harbored very few non-synonymous
mutations. Moreover, these rare mutations were not predicted to form neo-epitopes. To
determine if greater immunogenicity could supersede the immunosuppression in this
model and drive classical editing, I introduced ovalbumin as a “neo-antigen” to the 4662
cell line. These tumors were rapidly rejected in a CD8 T cell-dependent manner.
Moreover, mixed tumor implants of Ova-positive and Ova-negative 4662 revealed that
this initial CD8-mediated response was highly specific, allowing outgrowth of Ovanegative cells and restoration of immunosurveillance. I further determined that priming
by Ova4662 permitted a T cell response upon re-challenge with parental 4662 cells
despite the immunosuppressive microenvironment, indicative of epitope spread to
otherwise quiescent antigens. Thus, PDA is immunologically “cold,” but a strong
antigen restores immunosurveillance even in the presence of an immunosuppressive
microenvironment. Therefore, antigen strength rather than immunosuppression
principally determines the immunological fate of a tumor.
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Fig 1. Intratumoral T cell infiltration in Gem/CD40-treated KPC mice is dependent
upon ablation of macrophages. (A) Experimental schematic of treatments administered
in KPC tumor-bearing mice. CEL, clodronate-encapsulated liposomes. (B) H&E (top
panel) and CD3 immunohistochemistry (bottom panel) of tumor-bearing KPC mice
treated with various combinations of gemcitabine, CD40 (“FGK”), and CEL. (C,D,)
Quantification of tumor-infiltrating T cell subsets across treatment groups according to
immunohistochemistry.
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Chapter 2: Materials and Methods

Human RNA-Seq Gene Expression Data
Gene expression for 6 human tumors (PDA, melanoma, squamous carcinoma of the lung,
adenocarcinoma of the lung, kidney clear cell carcinoma, and low-grade glioma) in
normalized gene abundance estimates (rsem.genes.normalized_results) were downloaded
from the NIH TCGA Research Network through GDAC Firehose
(http://gdac.broadinstitute.org/) and included all available Illumina HiSeq 2000 Level 3 genelevel data. Normal tissue samples were excluded from the analysis. A cytolytic signature was
calculated as the log-average of granzyme A (GZMA) and perforin 1 (PRF1) expression per
sample as previously described (Rooney et al., 2015). Similarly, a CD8 signature was
calculated as the log-average of CD8A and CD8B expression. To compare gene signature
expression among different cancer cohorts, one-way ANOVA was performed and a
Dunnett’s multiple comparisons test was used to calculate significant differences from PDA.

Animals
All mouse protocols were approved by the Institutional Animal Care and Use Committee
of the University of Pennsylvania. Survival data and primary cell lines were generated
from KrasLSL-G12D/+, Trp53LSL-R172H/+, Pdx1-Cre (KPC) mice (Hingorani et al., 2005) bred
in-house, backcrossed more than ten generations with syngeneic mice, and found to be
congenic to the syngeneic background as assessed at the DartMouse™ Speed Congenic
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Core Facility at the Geisel School of Medicine at Dartmouth. DartMouse uses the
Illumina GoldenGate Genotyping Assay to interrogate 1449 SNPs spread throughout the
genome. The raw SNP data were analyzed using DartMouse’s SNaP-Map™ and MapSynth™ software, allowing the determination for each mouse of the genetic background
at each SNP location. Tumor implant studies were performed using eight- to ten-weekold female C57BL/6 mice purchased from Jackson Laboratories.

Collection of Tissue Samples from Mice
Whole pancreata of KPC mice or subcutaneous tumors were dissected and processed as
previously described (Bayne et al., 2012). Tissues were extensively minced with a razor
and incubated in collagenase IV solution (1mg/ml in RPMI media) for 45 minutes at
37°C. The dissociation reaction was stopped by 1:1 dilution with cold FCS, followed by
passing cells through a 70μm cell strainer. The cell suspension was carefully passed
through a 27g needle, washed twice in DMEM, and passed through a second strainer
prior to use for flow cytometry or cell culture.
Spleens were homogenized through a 70μm strainer and carefully passed through a
27g needle to create a single-cell suspension. Following centrifugation, pelleted cells
were incubated with ACK lysis buffer (BioWhittaker) at a 1:10 ratio for 8 minutes to
induce red blood cell lysis. Cells were washed twice in RPMI prior to use for flow
cytometry.
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Peripheral blood was collected by tail vein into heparinized microhemtocrit capillary
tubes. Blood was removed from the tubes by centrifugation and similarly prepared for
flow cytometry with ACK lysis buffer and serial washes in RPMI media.

Preparation of Cell Lines
Tumors from the pancreata of KPC mice were excised with sterile scissors and
extensively minced prior to dissociation in 1mg/ml collagenase IV solution at 37°C for
45 minutes. Dissociated cells were passed through a 70um strainer and plated in serumfree DMEM at varying concentrations in a 6-well plate. Cells were maintained in serumfree media for at least two weeks and passaged to higher volume flasks for expansion in
DMEM + 10% FCS. Cells were used for implant studies at low (3-5) passages. Cell
lines were validated by RT-PCR to assess for Cre-mediated recombination of the mutant
Kras and Trp53 alleles. Primer sequences to detect recombined Kras and Trp53 loci are
as follows: forward 5’-gtc ttt ccc cag cac agt gc-3’ and reverse 5’-ctc ttg cct acg cca cca
gct c-3’, and forward 5’-agc ctg cct agc ttc ctc agg-3’ and reverse 5’-ctt gga gac ata gcc
aca ctg-3’, respectively.

In vivo mouse studies
T cell depletion of either KPC or C57BL/6 mice was achieved by intraperitoneal
injection of 0.2 mg of αCD8 (2.43), αCD4 (Gk1.5), or an IgG2b isotype control (LTF-2)
diluted in 100ul sterile PBS. All antibodies were purchased from BioXcell. For long31

term depletion in KPC mice, pups were administered a first dose at 4 weeks of age and
every 4 days thereafter until euthanasia. The initial depletion was verified by flow
cytometry of peripheral blood, and then reassessed every 2 or 3 weeks thereafter for the
duration of the study; blood was drawn prior to re-administration of the antibody to
assess peak T cell levels. For subcutaneous implant studies, mice were pre-treated with T
cell-depleting antibodies 2 days prior to tumor challenge and then every 4 days thereafter.
T cell depletion was confirmed by peripheral blood samples and end-of-study flow
cytometry. NK cell depletion was achieved by intraperitoneal injection of 0.2mg PK136
mAb (BioXCell) on days -1, 0, +1, and every 5 days thereafter. NK cell depletion was
confirmed by end-of-study flow cytometry on splenocytes.
KPC mice were enrolled in survival studies on a rolling basis, as described (Beatty et
al., 2011). Genotyped mice were allocated to treatment groups in a randomized fashion,
and monitored for development of tumor-associated morbidities including ascites,
lethargy, depression, or a tumor volume >1000mm3. Mice were censored for unrelated
morbidities, including prolapsed rectum or penis, non-PDA tumors (thoracic and
submandibular), and malocclusion.
Diagnosis of PDA in KPC mice was performed by abdominal ultrasound beginning at
7-8 weeks of age and every other week thereafter; between scheduled ultrasounds, mice
were additionally monitored by palpation and imaged when indicated. Ultrasound was
performed with a Vevo 2100 imaging system with a 55MHz MicroScan transducer
(Visual Sonics). Tumors were visualized and reconstructed using the integrated Vevo

32

Workstation software package to assess tumor volume. Mice were censored from the
diagnostic study if euthanized for non-PDA morbidity prior to a definitive diagnosis.
Subcutaneous implant studies were performed using PDA cell lines titrated to grow
with similar kinetics over 21-24 days, at a relatively low dose (<106 cells) to avoid
ulceration and permit any relevant immune response (4662: 5x105 cells; 1638: 7.5x105
cells; 1262: 2x105 cells; 1493: 3x105 cells). Cells were harvested at 80-90% confluence,
washed twice in sterile DMEM, and administered subcutaneously into the right flank in
100ul sterile DMEM. Caliper measurements were obtained of the longest tumor
dimension (length) and the perpendicular dimension (width) every 3 to 4 days. Tumor
volume was calculated as (L x w2)/2.

Antibodies
The following mAb were used for flow cytometry: from BD Biosciences, mIgG2a, κ isotype
control (MOPC-173, FITC), αCD3e (145-2c11, FITC), αCD31 (MEC 13.3, FITC), αCD44
(IM7, FITC), αCD45 (30-F11, FITC), αCD45 (30-F11, PE), αCD3 (145-2C11, PerCP),
αCD45 (30-F11, PercP), αCD8a (53-6.7, PE-Cy7), αCD45 (30-F11, PE-Cy7), αCD45 (30F11, APC), αCD11b (M1/70, APC-Cy7), αCD45 (30-F11, APC-Cy7), αCD11c, (HL3,
V450), and αCD4 (RM4-5, V450); from BD Horizon, Streptavidin-V450; from eBiosciences,
αCD8a (53-6.7, PE); from Biolegend, αH2-Db-Biotin (KH95), αKi-67 (16A8, FITC), αH2-Kb
(AF6-88.5, FITC), αOVA-H2-Kb (25-D1.16, APC), αCD90.2 (53-2.1, PerCP), αIFN-γ
(XMG1.2, PE-Cy7), αI-A/I-E (M5/114.15.2, PE-Cy7), αPD-L1 (10F.9G2, APC), αGranzyme
B (GB11, AlexaFLuor 647), and αTbet (4B10, Brilliant Violet 421). H2-Kb Ova Tetramer
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(SIINFEKL–PE) and the MHC class I negative tetramer (APC) were purchased from MBL
International Corporation (Beckman Coulter). Viability of cells was determined by staining
with either 7-aminoactinomycin D (7-AAD; BD Biosciences) or Live/Dead Fixable Aqua
Dead Cell Stain Kit (Life Technologies).

Neo-epitope prediction pipeline
Genomic DNA from KPC mouse tumor cell lines or mechanically digested control tissue
(KPC spleen) was extracted using the PureLink Genomic DNA minikit (Invitrogen) and
assessed for purity and yield using a NanoDrop 2000c spectrophotometer. DNA integrity
was further assessed by electrophoresis on 1% agarose gels and DNA concentration was
determined using a Qubit dsDNA BR Assay Kit (ThermoFisher Scientific). Exome
enrichment was performed using an Illumina Paired End Sample Prep Kit and library
sequencing was performed using a 100 bp paired-end protocol on the Illumina platform
(HiSeq2500) (High-Throughput Sequencing Center, Beijing Genomics Institute at
Children’s Hospital of Philadelphia). Sequence alignment and processing were performed
as previously described (Westcott et al., 2015). Single nucleotide variants in tumor
samples were identified using MuTect (version 1.1.7) (Cibulskis et al., 2013) with default
filters against normal splenocytes from KPC mice (for PDA lines) or C57BL/6
splenocytes (for B16 melanoma). Variants were annotated using SnpEff (version 4.1 L)
with default settings and filtered against known SNPs. 8-14 amino acid sequences
surrounding surviving missense mutations were then ranked for binding affinity to MHC
class I H-2Db and H-2Kb molecules using the consensus method provided by the Immune
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Epitope Database and Analysis Resource (IEDB) (http://www.iedb.org/). Using two
thresholds of potential binding affinity, peptides with a median half-maximum inhibitory
concentration (IC50) of less than 50nM or less than 100nM were identified as potential
neo-epitopes. The IC50 for each peptide was considered the median value of individual
prediction method results provided by the IEDB consensus method.

Retroviral transduction of 4662 cell line with Tdt-Ova
The pMX-Tdt-Ova plasmid containing a pMXs retroviral backbone with full-length
ovalbumin fused to Td-Tomato was a kind gift of Dr. Li Wang (Dartmouth University).
70-90% confluent HEK 293T packaging cells were transfected with the plasmid and a
packaging mix (pCMV-Gag/Pol and pVSV-G) using lipofectamine to produce viral
supernatant. 4662 cells were plated in a 24-well plate until reaching 50% confluence.
Cells were washed, and 1ml of a 1:2 virus:DMEM solution was incubated for 36-48
hours (diluted at 24 hours with an additional mL of DMEM). Cells were passaged to
larger flasks, and sorted by flow cytometry for the top 15% of Td-Tomato-expressing
cells to create an enriched cell line. Cells were then single-cell sorted into a 96-well plate
to create single-cell clones of TdT-Ova4662.

IFNγ Stimulation Assay
To assess for processing and presentation of SIINFEKL peptide on MHC class I under
conditions of IFNγ stimulation, 4662 parental Tdt-Ova transduced clones (V6, G7, and
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G10 single-cell clones) were plated in T25 flasks, and at 50% confluence, 500units/l of
IFNγ (R&D systems) were added to one flask of each cell line and incubated for 24
hours, while a duplicate flask remained unstimulated. As a positive control, SIINFEKL
peptide was then added at 10ug/ml for 30 minutes at 37°C to stimulated and unstimulated
4662 cells. Cells were then trypsinized, washed and stained for viability and Ova-H2-Kb
by flow cytometry.

Flow Cytometry and Tetramer staining
Following preparation of a single-cell suspension, up to 5x106 cells were plated per well
in a 96 well plate, washed, and stained with fluorochrome-labeled antibodies at 4°C for
20 minutes in a buffer of PBS/1%FCS and 0.5mM EDTA. For tetramer stains, prior to
surface staining, cells were incubated at 37°C with positive or negative tetramer at 1:100
in FACS buffer, and then diluted with a 2x concentrate of the remaining surface stains.
Cell were run on a FACSCanto flow cytometer (BD Biosciences) and analyzed with
Flowjo software.

Intracellular Cytokine Stimulation Assay
A single cell suspension was prepared of tumor and spleen and samples were plated in
duplicate in a 96-well plate for stimulated and unstimulated treatments. Stimulation was
performed using RPMI-1640 media supplemented with L glutamine, gentamicin, 10%
FCS, and 0.05mM 2-ME.; for unstimulated samples, GolgiStop (Monensin) was added to
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media at 1:150, and stimulated samples were additionally incubated with PMA (1mg/ml
stock) at 1:20,000 and ionomycin (1mM stock) at 1:100. Both stimulated and
unstimulated samples were incubated for 5 hours at 37°C. Viability was then assessed
using Live/Dead Fixable Aqua Dead Cell Stain Kit, followed by surface staining and
fixation/permeabilization for intracellular staining.

Statistics Analysis
Variations between two groups were determined by an unpaired two-tailed Student t test.
Differences between three (or more) groups for one factor were analyzed by one-way
ANOVA, with Tukey multiple comparison test used as a post hoc test to evaluate
differences between any two groups. To study the effect of multiple factors across
multiple groups, two-way ANOVA was utilized with the Sidak’s multiple comparison
test for post hoc evaluation of differences between any two groups. Tumor growth
curves were analyzed by two-way ANOVA, with Tukey multiple comparisons of means
used as a post hoc test to determine differences between any two groups. Survival curves
were assessed by the log rank (Mantel–Cox). All statistical analyses were performed
using GraphPad Prism 6 (GraphPad) except two-way ANOVA and related post hoc
testing that were performed on R Statistical Software (R Core Team). P ≤ 0.05 indicates
differences that are statistically significant.
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CHAPTER 3 – The natural history and progression of PDA are independent of T cell
immunosurveillance.
*The majority of these studies have been described in the manuscript submitted for
publication

INTRODUCTION
The prevailing theory of cancer immunosurveillance asserts that the adaptive
immune system can recognize and eliminate nascent cancer cells, but tumor clones with a
selective advantage may escape recognition by the immune system, leading to
unrestrained tumor growth (Schreiber et al., 2011; DuPage et al., 2012). This concept,
supported by seminal studies in carcinogen-induced mouse models of tumorigenesis
(Shankaran et al., 2001; Matsushita et al., 2012), has led to the immunoediting
hypothesis: escaped tumors are understood to be sculpted or “edited” under the
Darwinian-like pressure exerted by tumor-specific T cells. Key evidence for
immunoediting includes: (i) in vivo models in which tumors emerge at a higher frequency
and decreased latency in mice lacking T cells (Shankaran et al., 2001; DuPage et al.,
2011; DuPage et al., 2012) and (ii) observations that cancer cells isolated from
progressively growing tumors in T cell-depleted hosts are rejected upon implantation in a
T cell-replete, but not T cell-deficient, host. The primary model that established this
hypothesis, however, resulted in a “hypermutated” tumor phenotype, exhibiting a ten-fold
higher mutational burden than even smoking-induced lung cancers (Matsushita et al.,
2012). Thus, the model that generated the immunoediting hypothesis may not be
representative of most human malignancies.
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This theory has remained untested across a wide spectrum of mouse models,
including spontaneously arising carcinomas driven by oncogenes at the endogenous
locus; given that a majority of solid human malignancies develop in this fashion,
additional studies are imperative to understanding the full spectrum of host-tumor
interactions. Moreover, the implication of variable tumor histologies and
microenvironments has not been addressed in the current hypothesis of
immunosurveillance.
I reassessed the cardinal features of cancer immunosurveillance using a
genetically engineered mouse model of PDA that mimics the human disease with high
fidelity and permits inspection of T cell infiltration from inception to invasion of mutant
Kras-driven tumors (Hingorani et al., 2003; Clark et al., 2007). In the “KPC” model of
PDA, which includes targeted pancreatic expression of mutant Kras and p53, tumors arise
in immune competent hosts in the absence of carcinogens and in the setting of an
oncogene expressed at the endogenous locus (Hingorani et al., 2005). PDA in both
humans and KPC mice is characterized by a dense, desmoplastic stroma, which features a
prominent network of immunosuppressive leukocytes driven in part by the tumor itself
(Clark et al., 2007; Olive et al., 2009). Tumor-derived GM-CSF, for example, acts in the
tumor microenvironment to recruit myeloid-derived suppressor cells that inhibit T celldependent, perforin-mediated cytotoxicity (Bayne et al., 2012; Pylayeva-Gupta et al.,
2012). These data suggest that the immunosuppressive microenvironment mediated by
PDA has the ability to impede or even circumvent immunosurveillance.
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In the following studies, I tested the hypothesis that the immunosuppressive
microenvironment exhibited by PDA would preclude T cell immunosurveillance at its
inception, thereby preventing sculpting of the tumor. I theorized that PDA tumors
represent a site of immunological ignorance, which may paradoxically permit
development of tumors that retain strong antigens in immune-competent hosts. I utilized
both the KPC model as well as implantable studies of KPC-derived cell lines to assess the
sculpting effect of the immune system on the natural history of this disease at both an
organismal and cellular level. To study changes in the genomic landscape potentially
induced by T cells, I utilized whole exome sequencing (WES) of PDA cell lines derived
from immune-competent and immune-compromised KPC hosts. Through several
collaborative efforts, I further utilized various mechanisms of microenvironmental
disruption and thereby determined the degree of immunogenicity shrouded within an
immunosuppressive network.

RESULTS
In the KPC model, effector T cell infiltration is modest even at the earliest stages of
neoplasia (Clark et al., 2007; Clark et al., 2009; Beatty et al., 2011), similar to the dearth of T
cells observed histologically in other oncogene-driven cancer GEMMs (Akbay et al., 2013;
Skoulidis et al., 2015). To compare the T cell-poor phenotype of the KPC model to human
PDA, I assisted fellow graduate student Tim Chao in analyzing The Cancer Genome Atlas
(TCGA) for expression data of 147 cases of human PDA. We observed a statistically lower
level of CD8 expression within PDA tumors compared to melanoma, renal cell carcinoma, or
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lung cancer – three tumors for which impressive clinical responses to immune checkpoint
blockade have been observed (Fig 2). Moreover, PDA tumors exhibit relatively low levels of
granzyme A and perforin-1, which together constitute a normalized cytolytic expression
signature that distinguishes immunologically “hot” tumors from “cold” tumors (Rooney et
al., 2015; Sharma and Allison, 2015). Thus, the low quantity and quality of T cells in both
the KPC model and human PDA suggest that immunologically inert cancers may not
undergo classical immunoediting driven by potent T cell immunity.
Modeling my approach after the seminal immune studies of MCA-induced
tumorigenesis, I evaluated immunosurveillance in KPC mice. For MCA tumors, an increased
tumor incidence and decreased survival are observed in T cell-deficient mice; however, these
carcinogen-driven cancers have a hypermutator phenotype and strong T cell reactivity
(Matsushita et al., 2012). To determine whether T cells play a similar role in PDA, I serially
administered CD4- and CD8-depleting antibodies or an isotype control to juvenile (3-5 weekold) KPC mice (Fig 3A). Treated mice were then monitored by ultrasound for the
development of PDA and evaluated for signs of morbidity (Fig. 3B). Efficacy of antibodymediated T cell depletion for the duration of the study was confirmed (Fig. 4). Tumor-free
survival (i.e., time to diagnosis) and overall survival were statistically indistinguishable
between CD4/CD8-depleted mice and isotype-treated mice (Fig. 5). Likewise, no difference
was observed for tumor-free and overall survival in mice exclusively depleted of CD8 T cells
(Fig. 5). Tumors from each cohort exhibited similar histology (Fig. 6), and flow cytometry
demonstrated the same prominent leukocytic infiltrate (Fig. 7) in isotype control vs. T celldepleted mice. These results differ from classic mouse sarcomas in which immunodeficient
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hosts exhibit a greater frequency of tumors and decreased survival (Shankaran et al., 2001;
DuPage et al., 2012).
To test further for T cell immunosurveillance in PDA, I then created cell lines derived
from the tumors of immune-competent KPC mice (Fig. 8). Following tumor harvest and
elimination of stromal elements in culture, a representative line (4662) was selected and
verified to express the recombinant mutant alleles by RT-PCR. This low-passage cell line
was then implanted subcutaneously into T cell-depleted or isotype-treated syngeneic mice,
and followed tumor growth for 21-24 days by caliper (Fig. 8). Similar to the findings in the
autochthonous KPC model, tumor growth of 4662 cells was unaffected by T cell depletion of
recipient mice (Fig. 9). Tumor growth featured rapid recapitulation of the dense, stromal
microenvironment of the original tumor despite elimination of non-tumor cells from the cell
line (Fig. 10). Similarly, the extracellular matrix of 4662 PDA tumors is extensive (Lo et al.,
2015).
To exclude the possibility that the initial bolus of 5x105 tumor cells overwhelmed an
otherwise relevant immune response, I also tested a lower subcutaneous dose of 105 4662
cells. Again, tumors grew with similar kinetics in the presence or absence of T cells (Fig.
11). 4662 tumors also grow with similar kinetics in NOD/SCID/γc-/- immune-incompetent
mice compared to wild-type mice (Lo et al., 2015). To assess whether the negative immune
checkpoint molecules PD-1 and CTLA-4 were influencing tumor rejection as observed in the
MCA model (Gubin et al., 2014), I also repeated these experiments in the presence of mAb
blocking PD-1 and CTLA-4 with the assistance of fellow graduate student Rafael Winograd.
In our system, this treatment did not enable tumor rejection (Fig. 12). Furthermore, 4662
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cells remained responsive to IFNγ in upregulating MHC class I (but not MHC class II) (Fig.
19, see chapter 4), indicating that this cell line is theoretically susceptible to T cell-mediated
recognition.
To elucidate the mechanism of this inevitable tumor outgrowth in the KPC model,
immunoediting was assessed directly by generating cell lines from tumors arising in
chronically T cell-depleted KPC mice (validated by flow cytometry, Fig. 13) and implanting
them in immune-competent or T cell-depleted syngeneic hosts (as previously described, Fig.
8). Each cell line derived from a T cell-depleted KPC mouse (1262, 1493, and 1638) grew
with similar kinetics regardless of the immune status of the recipient mouse, and tumor
regression was not observed in any individual mouse (Fig. 14). These findings differ from
similarly designed experiments in the MCA model (Shankaran et al., 2001), implicating a
mechanism of tumor outgrowth other than immune editing.
I hypothesized that these divergent manifestations of cancer immune surveillance in
the Kras-driven PDA model and the prior MCA studies may reflect differences in the
incidence of T cell neo-epitopes arising from tumor missense mutations (Wolfel et al., 1995;
Robbins et al., 1996; Dubey et al., 1997; Matsushita et al., 2012). Such mutations drive
strong anti-tumor T cell responses in the MCA model, which features a high level of nonsynonymous tumor mutations, and lead to antigen loss as a means of escape consistent with
immunoediting (Matsushita et al., 2012). In collaboration with fellow graduate student
Andrew Rech and the BGI sequencing core at the Children’s Hospital of Philadelphia, we
therefore performed whole exome sequencing (WES) on 4662 PDA cells as well as the three
PDA cell lines derived from T cell-depleted KPC mice. As anticipated from WES analysis of
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tumors from other Kras-driven GEMMs (Westcott et al., 2015) and human PDA (Jones et al.,
2008; Sausen et al., 2015; Waddell et al., 2015), we found that 4662 PDA cells exhibited a
relatively low mutational burden. Among the 10 non-synonymous mutations identified, none
were predicted to comprise an 8-14 amino acid epitope with high affinity for MHC class I
H2-Db or H2-Kb molecules based on the previously defined cutoff of 50nM (Fig 15)
(Matsushita et al., 2012; Westcott et al., 2015). T cell-depleted PDA cell lines 1262, 1493,
and 1638 also exhibited a low mutational burden with 16, 16, and 34 non-synonymous
mutations, respectively, with either 0 (1262) or 1 (1493 and 1638) of these mutations
predicted to generate a neo-epitope (Fig. 15). Similar findings were obtained using a binding
affinity cutoff of 100nM (Fig. 15). As a positive control in our analysis pipeline, we
determined that murine B16-F10 melanoma tumors expressed 1077 non-synonymous
mutations, 13 of which were predicted to trigger specific T cell reactivity at the 50 nM cutoff,
or 21 at the 100nM threshold (Fig. 15). A prior study of B16-F10 melanoma tumors similarly
found >500 non-synonymous mutations, and at least 30% of those experimentally tested
were predicted to trigger specific T cell reactivity (Castle et al., 2012). In further contrast,
MCA tumor cell lines established from immunodeficient Rag2-/- mice exhibited >2000
somatic, non-synonymous mutations (Matsushita et al., 2012). My findings, therefore,
suggest that the T cell-independent growth properties of KPC-derived PDA cell lines may be
a consequence of the low incidence of missense mutations and subsequent lack of neoepitopes in these tumors.
Even though the human and mouse data suggest an immunologically “cold”
tumor, during the course of my research I discovered that otherwise quiescent antigens
(or self-antigens) could be unveiled by manipulating the tumor microenvironment. Long44

term depletion of CD4+ T cells in KPC mice surprisingly resulted in prolonged overall
survival, an effect I knew to be abrogated in mice depleted of both CD4 and CD8 cells
(Fig. 16A). These data suggested a CD4+ cell population that inhibits an otherwise
relevant CD8 T cell response, albeit weak. By serial ultrasound, I determined that the
survival benefit of anti-CD4 treatment was due to a delayed onset of disease, rather than
slowing tumor progression (Fig. 16B and 16C).
In collaboration with the Pasca di Magliano laboratory at the University of
Michigan, we validated this early-stage impact of CD4 cells in a genetic model of
depletion (Fig. 17) (Zhang et al., 2014). This model provides an excellent system for
studying the early stages of tumorigenesis, as PDA is driven solely by doxycyclineinducible KrasG12D in these so-called iKras mice; without concurrent mutation or
deletion of p53, tumorigenesis progresses slowly in this model, such that mice develop
early PanIN-stage lesions over prolonged periods of time (Hingorani et al., 2003). We
discovered that, in this model, CD4 cells were in fact required for progression to PanINstage lesions. Even in the context of cerulein-induced pancreatitis to drive
carcinogenesis, the tissue damage and inflammation seen in iKras/CD4-/- mice resolved
quickly, such that the pancreas was histologically normal at a timepoint when CD4replete iKras mice demonstrated severe histologic aberrations including acinar-to-ductal
metaplasia (ADM) and multiple PanIN lesions. Early timepoints post-induction revealed
significant cleaved caspase 3 (CC3) staining in CD4-null mice, whereas the CD4-replete
iKras cohort demonstrated rare CC3 staining and significant proliferation by Ki67
staining in the epithelial compartment. In accordance with my own findings, this effect
was abrogated upon CD8 depletion, such that iKras/CD4-/- pancreata histologically
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resembled the iKras mice following induction of pancreatitis. Thus, two different model
systems of CD4 deficiency and tumor induction demonstrate that CD8 T cells are able to
inhibit the development of PDA; this suggests that antigens are in fact present and able to
be recognized through manipulation of the tumor microenvironment. The sequencing
data indicate a dearth of strongly immunogenic neo-antigens in this model, implicating
weak antigenicity in the failure of T cell surveillance at baseline, but nevertheless
providing productive responses upon disrupting the CD4-mediated microenvironment.
We sought to determine if manipulation of T cell function could likewise elicit a
response against weak antigens not recognized at baseline. As described above, PD-1
and CLTA-4 blockade were insufficient to induce a response (Fig. 12). However,
through collaboration with fellow graduate student Rafi Winograd, we studied the effect
of a potential “vaccine” in conjunction with checkpoint inhibition, as described in his
thesis work and our published data (Winograd et al., 2015). This cocktail included
gemcitabine and abraxane chemotherapy to induce cell death and release of antigens, in
combination with CD40 therapy to drive licensing of antigen-presenting cells (Beatty et
al., 2011; Vonderheide et al., 2013). In the joint setting of immunogenic cell death,
checkpoint inhibition, and improved T cell priming, weaker antigens were able to elicit
productive T cell responses, including a CD8-dependent memory response upon rechallenge.
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DISCUSSION and CONCLUSIONS
According to these studies of the KPC model and KPC-derived cell lines, T cell
immunosurveillance in PDA does not appear to manifest in the classically described
immunoediting process. Unlike Schreiber and colleagues, T cell-depleted mice did not
demonstrate decreased survival. Although a cell line derived from an immune-competent
mouse (4662) mimicked the “escape” phenotype seen in the MCA model, whereby
implantation of tumor cells in an immune competent host resulted in tumor outgrowth
(suggestive of prior sculpting and immune pressure), concurrent studies with cell lines
from T cell-depleted KPC mice suggest a different mechanism of failed surveillance.
According to immunoediting standards, a tumor arising in a T cell-depleted environment
should maintain immunogenicity and be rejected in an immune-competent recipient; in
my data set, tumor regression was never observed upon transfer of any of the three T celldepleted cell lines.
The collective data herein suggest that the ultimate failure of T cell surveillance in
KPC mice must result from a different mechanism than immune-driven sculpting and
escape clones. Two explanations could result in these aberrant findings: 1) the
immunosuppressive microenvironment arises in tandem with tumor onset, such that the
tumor is protected at the outset from any immune pressure (and that this
microenvironment is recapitulated by KPC-derived cell lines upon implantation), or 2)
these tumors are immunologically “cold” and therefore remain invisible to circulating T
cells. These two mechanisms are not mutually exclusive; the degree of “coldness” and
the extent of immunosuppression remain unclear based on these studies alone.
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To deconstruct the contribution of these two factors in failed T cell surveillance of
PDA, I used a genomic approach. Neo-antigens derived from non-synonymous
mutations are described as the primary source of immunogenicity in cancer, because they
encode novel proteins that are seen as “foreign” by the immune system (Sette et al., 1994;
Castle et al., 2012; Matsushita et al., 2012). In contrast, self-antigens expressed by tumors
may be subject to central tolerance (Pardoll, 2003; Pradeu and Carosella, 2006). Whole
exome sequencing of the 4662 line revealed very few non-synonymous mutations, and a
well-established epitope prediction pipeline suggested that none would generate peptides
that bind MHC class I with high affinity. Although this lack of immunogenic neoantigens might be expected in a tumor that arose in the context of immune pressure,
tumors derived from T cell-depleted KPC mice could theoretically retain their
immunogenic neo-antigens. However, my three KPC cell lines that arose in a T cell-free
environment did not have a statistically higher number of mutations or predicted
epitopes. Thus, it appears that KPC tumors are indeed immunologically “cold” and
represent a sub-type of tumors that lack a blatant “red flag” for immune recognition.
Interestingly, a recent study strongly supports this finding. Lung adenocarcinomas driven
by oncogenic Kras or carcinogen-induced Kras demonstrated markedly different genomic
landscapes. Similar to the contrasting mutational burden in MCA-driven tumors and our
oncogene-driven model, this study found a dramatic disparity in mutational burden based
on the source of tumorigenesis (Westcott et al., 2015).
Despite the bleak outlook this might suggest for immunotherapy in the context of
PDA, I also found that the microenvironment indeed appears to contribute to immune
failure, and may provide another avenue for immunotherapy. CD4-depleted KPC mice
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demonstrated a delayed onset of tumorigenesis and overall increased survival, a finding
corroborated by our collaborators at the University of Michigan (Zhang et al., 2014). In
both models of CD4 depletion, CD8 cells conferred protection against PDA development;
without CD8 cells, the protective benefit of CD4-depletion was lost. Therefore, some
quiescent epitopes must exist in the KPC model of PDA, albeit not as profound as neoantigens.
It appears that CD4-mediated immunosuppression is capable of restraining an
otherwise productive CD8 T cell response against weak antigens. Our lab continues to
work on determining the CD4+ cell type responsible for this phenomenon, which could
clarify novel targets in pancreatic cancer. The CD4+ cell compartment is very complex,
including Th1 or Th2 helper T cells, Th17 cells, regulatory T cells, and even a subset of
macrophages; the Gk1.5 antibody used in our study would deplete any of these cell types.
Several recent papers help clarify which of these populations may drive the
immunosuppressive effect we have observed.
As our lab has previously established, Foxp3+ regulatory T cells (Tregs) are
present even at the earliest PanIN stages of PDA in the KC model of tumorigenesis,
which strongly implicates this population in mediating a suppressive network. In a
histopathologic study of human PDA samples, Hiraoka et al. discovered that CD4+
CD25+ Foxp3+ cells indeed increased in tandem with the stages of PDA development,
from non-neoplastic inflammatory pancreata to frank carcinoma, and that this increase
was statistically significant (p<0.0001) (Hiraoka et al., 2006). This observation
correlated inversely with the infiltration of CD8+ cytotoxic T cells, which were prevalent
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at pre-malignant PanIN stages and tapered during the progression to full-grade
adenocarcinoma. Importantly, the degree of Foxp3+ infiltrate correlated strongly with a
better prognosis (p<0.0001), which mirrors the findings of improved survival in our
CD4-depleted KPC mice.
This population may indeed represent the most likely culprit in a CD4-mediated
immunosuppressive microenvironment, but it is a difficult population to target. CTLA-4
blockade has been shown to deplete these cells from draining lymph nodes in an FCdependent manner (Simpson et al., 2013), but this marker is expressed on many other cell
types and therefore lacks specificity. A more targeted approach to ablating regulatory T
cells involves crossing the KPC model with Foxp3-DTR transgenic mice, and monitoring
survival of these mice following administration of diphtheria toxin. This study is
currently ongoing in our laboratory.
IL-17-producing CD4+ cells have likewise been implicated in the progression of
pre-neoplastic lesions in the pancreas, and represent another potential mechanism behind
CD4-mediated immunosuppression. Differentiation of CD4+ helper cells to a Th17
phenotype can be driven by IL-6 and TGF-β signaling within the tumor
microenvironment, and this correlates strongly with chronic inflammation. Using
KCmist1 mice, the Leach laboratory demonstrated by flow cytometry a high proportion
of CD45+ IL-17A+ cells within the pancreata of mice with chronic pancreatitis and
oncogenic Kras; moreover, the combination of cerulein-induced pancreatitis and Kras
activation increased these IL-17-A levels synergistically (McAllister et al., 2014). Since
both CD4+ cells and γδTCR+ cells can produce this cytokine, McCallister et al. depleted
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mice weekly with the same GK1.5 antibody utilized in our long-term ultrasound study,
which resulted in a significant delay in PanIN formation in these mice.
A similar finding was observed in lethally irradiated KCmist mice receiving bone
marrow transplants from IL-17KO mice. 8 weeks after induction of Kras, these mice
demonstrated fewer ADM and PanIN lesions in their pancreata by histopathology.
Pharmacologic inhibition of IL-17 likewise slowed PanIN formation, suggesting this
treatment may recapitulate the phenotype we observed in our CD4-depleted KPC mice.
However, no dependence on CD8+ cells was observed in this model, so the mechanism
of IL-17 may be pro-inflammatory rather than immunosuppressive.
In collaboration with fellow graduate student Rafael Winograd, I also
demonstrated that this immunosuppression and lack of immunogenicity can be overcome
by stimulating T cells with a multifaceted vaccine approach (Winograd et al., 2015).
Combining checkpoint inhibition (which was alone insufficient to drive anti-tumor
responses) with chemotherapy and CD40 therapy allowed for long-term tumor
regressions and establishment of memory responses in T cells – notably in mice with an
intact CD4 compartment. Thus, multiple mechanisms can be used to drive immune
responses against weak antigens despite a baseline lack of T cell reactivity, low
immunogenicity, and an immunosuppressive microenvironment.

51

FIGURES

C D 8 S ig n a t u r e

PDA

M e la n o m a

****

Lung squamous

ns

L u n g a d e n o c a r c in o m a

ns

K id n e y c .c . c a n c e r

****

L o w g r a d e g lio m a

**
0

500

1000

1500

2000

4000

6000

8000

lo g - a v e r a g e g e n e a b u n d a n c e e s t im a t e

C y t o ly t ic S ig n a t u r e

PDA

M e la n o m a

****

Lung squamous

**

L u n g a d e n o c a r c in o m a

***

K id n e y c .c . c a n c e r

****

L o w g r a d e g lio m a

***
0

500

1000

1500

2000

4000

6000

8000

lo g - a v e r a g e g e n e a b u n d a n c e e s t im a t e

Fig 2. Human PDA does not express high levels of CD8 or markers of cytolytic
activity. CD8 (top) and cytolytic (bottom) signature expression for 6 human tumors
(PDA, N=147; melanoma, N=471; lung squamous, N=501; lung adenocarcinoma,
N=517; renal cell carcinoma, N=534; low-grade glioma, N=530). Box plots represent the
interquartile range and the whiskers represent the 5th-95th percentile of the log-averaged
gene signature abundance estimates. One-way ANOVA and Dunnett’s multiple
comparisons test were used to calculate a significant difference from PDA. ** indicates
P<0.01, *** represent P<0.001, and **** indicates P<0.0001.
52

A

B
BB

Liver
Normal Pancreas
Portal Vein

Aorta

Stomach

IVC

Fig 3. Experimental design for KPC survival studies. A) Syngeneic KPC mice treated
with an isotype control antibody, depleted of CD4 and CD8 T cells (αCD4/αCD8), or
depleted of CD8 T cells alone (αCD8) beginning at 3-5 weeks of age. N=19-21 mice per
cohort. Starting at 7-8 weeks of age, mice were monitored by ultrasound every other
week for tumor development and examined daily for morbidity. (B) Representative
image of a tumor at the time of diagnosis by abdominal ultrasound (volume=19mm3).
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Fig 4. Validation of T cell depletion by antibodies. (A) Peripheral blood of T celldepleted mice was monitored by flow cytometry beginning at the initial depletion and
every 2-3 weeks thereafter. Data for CD8+ T cells (left) and CD4+ T cells (right) for all
depleted mice are shown as the mean of the percentage of CD45+ leukocytes, pooling all
measurements for each individual mouse. For isotype-treated KPC mice, a randomly
selected subset (N=10) was assessed for T cell levels at an interim timepoint. P<0.0001
for all depleted cohorts compared to isotype control by one-way ANOVA. (B) T cell
levels in pancreatic (tumor) tissue and spleen at the time of harvest from isotype or T
cell-depleted mice enrolled in the survival study. CD4 and CD8 cells are expressed as a
percentage of viable (7AAD-) cells.
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Fig 5. Time to diagnosis and overall survival of KPC mice are independent of T
cells. Tumor-free survival according to ultrasound monitoring (time to diagnosis, top
panel) and overall survival according to daily monitoring (bottom panel) for the three
cohorts described in Fig. 3. P-values were determined by Log-rank (Mantel-Cox)
analysis. Table (below) shows median survival and median time to diagnosis for each
cohort.
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Fig 6. Pancreatic tumors of immune-competent and T cell-depleted KPC mice
demonstrate similar histology. Hematoxylin and eosin (H&E) staining of a
representative pancreatic tumor from each treatment cohort at the time of sacrifice (10x
magnification).
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Fig 7. Pancreatic tumors of immune-competent and T cell-depleted KPC mice
demonstrate similar leukocytic infiltrates. Flow cytometric analysis of tumors at the
time of euthanasia (4-6 mice per cohort) to assess infiltration by leukocytes (top left
panel, CD45+ cells as percent of viable cells), macrophages (top right panel, CD45+
CD19- F4/80+ as percent of viable CD45+ cells), and immature myeloid cells (bottom
panel, CD45+ CD19- Gr-1+ CD11b+ as percent of viable CD45+ cells). Data are shown
as whisker plots, with P-values determined by two-way ANOVA.
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Fig 8. Experimental design for implant studies of syngeneic PDA cell lines. Cell lines
were generated from immune-competent KPC mice or KPC mice serially depleted of
CD4/CD8 T cells beginning at 3-5 weeks of age as shown in Fig. 3. Cell lines were
implanted subcutaneously (s.c.) in syngeneic female mice pre-depleted of CD4 and CD8
T cells or administered an isotype control antibody (N=8-10 mice per cohort). Tumor
growth was measured by caliper over time and mice were monitored for overall survival.
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Fig 9. 4662 KPC cell line grows with the same kinetics upon implantation in
immune-competent or T cell-depleted mice. Subcutaneous tumor growth of 4662 PDA
cells in immune-competent syngeneic hosts (Isotype control) or immune-compromised
mice (αCD4/αCD8), shown for high inoculum (5x105 tumor cells). Growth data are
shown as spaghetti plots of individual mice, and P-value indicates analysis by two-way
ANOVA.
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Fig 10. 4662 implanted tumors recapitulate the microenvironment of autochthonous
KPC tumors. Histology of 4662 implanted tumors after 3 weeks of growth (left panel)
stained by H&E and Masson’s trichrome (top and bottom, respectively). Right panels
show H&E and trichrome staining of a representative autochthonous KPC tumor. All
images, 10x magnification.
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Fig. 11. Low doses of 4662 cells subcutaneously do not elicit T cell-mediated tumor
regressions or alter overall survival of recipient mice. Subcutaneous tumor growth of
4662 PDA cells in immune-competent syngeneic hosts (Isotype control) or immunecompromised mice (αCD4/αCD8), shown for low inoculum (105 cells). Mice were also
monitored for overall survival (bottom panel). Growth data are shown as spaghetti plots
of individual mice, and P-value indicates analysis by two-way ANOVA. Survival data
were analyzed by Log-rank (Mantel-Cox) test.
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P = 0.708
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Fig 12. PD-1 and CTLA-4 blockade do not impact 4662 tumor cell growth or overall
survival of recipient mice. C57BL/6 female mice were implanted subcutaneously with
parental 4662 cells as in Fig. 8 and were treated with a combination of antibodies
blocking PD1 and CTLA-4. A second cohort received an isotype control antibody. N=10
mice per cohort. Tumor growth by caliper was analyzed using two-way ANOVA (top),
and overall survival was assessed by Log-Rank/Mantel-Cox test (bottom).
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Fig 13. Validation of T cell-depletion in KPC mice used to generate T cell-depleted
tumor cell lines. Flow cytometry of peripheral blood from three mice chronically
depleted of CD4 and CD8 T cells and used to generate tumor cell lines 1262, 1493, and
1638. T cell levels are shown as a percentage of viable (7AAD-) CD45+ leukocytes at
various time points post-enrollment (~4 weeks of age) until tumor-associated morbidity
and euthanasia.
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Fig 14. T cell-depleted KPC tumor cell lines grow irrespective of recipient immune
status. Subcutaneous growth of CD4/CD8-depleted KPC cell lines (1262, 1493, and
1638; generated as described in Fig. 8) in immune-competent syngeneic isotype control
or αCD4/αCD8 mice. N=8-10 mice per cohort. P-values shown were generated by twoway ANOVA.
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Fig 16. Overall survival and time to diagnosis are increased in CD4-depleted KPC
mice. (A) Overall survival according to daily monitoring. (B) Tumor-free survival (i.e.
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(i.e. tumor progression). Data include CD4-depleted mice as well as the three cohorts
described in Fig 5. P-values were determined by Log-rank (Mantel-Cox) analysis.
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Fig 17. Genetic deletion of CD4 in iKras mice abrogates PanIN formation following
cerulein-induced pancreatitis. A) Schematic of CD4-null iKras mouse model and
induction of pancreatitis. B) H&E of pancreata of control littermates, iKras mice, and
CD4-null iKras mice at various timepoints following administration of cerulein. (Zhang,
et al., Cancer Immunology Research, 2014).
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CHAPTER 4 – Neo-antigens override the tumor microenvironment and dictate
immune surveillance in cancer.
*The majority of these studies have been described in the manuscript submitted for
publication

INTRODUCTION
Through the baseline studies of T cell immunosurveillance in the KPC mouse
model, I determined that immunoediting does not manifest in the conventional sense, and
that the dynamic interaction between the tumor and the immune system is more nuanced
and complex in this particular context. The intersection of tumor microenvironmental
factors, T cell-intrinsic factors, and sub-threshold immunogenicity results in failed
immunosurveillance without driving tumor escape. Which of these elements dominates
tumor outgrowth in PDA requires further exploration in order to understand the potential
for various immunotherapies.
Clearly the microenvironment and T cells can be inhibited or stimulated,
respectively, to drive an immune response; however, these factors may be secondary to
the sheer “invisibility” of tumors as predicted by the lack of mutation-derived epitopes.
In fact, the tumor microenvironment may very well be negligible in comparison, and T
cells may not be truly “dysfunctional” in PDA if provided the appropriate antigen.
Recent evidence suggests that neo-antigens are the “holy grail” of cancer immunology;
despite the eminent success of chimeric antigen receptors against various blood cancers
(Porter et al., 2011; Grupp et al., 2013), these therapies are limited to antigens expressed
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on the surface of tumor cells (e.g., CD19 on malignant B cells) and result in toxicity to
non-cancerous cells. Given these limitations, neo-antigens represent the next generation
of immunotherapy. By definition, neo-antigens are specific to the tumor cells, and they
may be intracellular or extracellular; the rate-limiting step is an ability to be processed
and presented by MHC class I alleles with significantly higher affinity than the wild-type
protein, as recently exemplified in MCA-induced sarcomas (Yewdell and Bennink, 1999;
Matsushita et al., 2012). Schreiber and colleagues determined that the loss of mutant βspectrin protein in escape clones was driven by high-affinity binding to the MHC class I
molecule in mice, and importantly resulted from a single amino acid change compared to
the wild-type protein. In a subsequent study, Schreiber and colleagues uncovered similar
neo-antigens by checkpoint blockade, suggesting that T cell tolerance or exhaustion were
co-determinants of immunoediting in this model (Gubin et al., 2014). Our model system
again deviated from these findings, such that a dearth of naturally occurring neo-antigens
(as suggested by sequencing) required additional T cell “help” in the form of CD40
antibodies and gemcitabine/abraxane to utilize weaker (self) antigens; again, these
findings implicate the immune-quiescence of the tumor itself in failed surveillance of
PDA, not its microenvironment or T cell-intrinsic dysfunction.
The preeminence of neo-antigens in driving immunosurveillance of human
cancers was highlighted by Brown and colleagues in their analysis of deep sequencing
data available through The Cancer Genome Atlas (Brown et al., 2014). Using another
epitope-prediction tool across human samples from six tumor types, they determined that
tumor mutational burden alone did not correlate with survival; rather, it was the presence
or absence of a predicted neo-epitope that held prognostic significance. Higher
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immunogenicity likewise correlated with CD8A expression, suggestive of a T cell
response. Moreover, immunogenicity resulted in the increased expression of T cell
exhaustion markers like PDCD1 and CTLA4, encoding the same checkpoint proteins
targeted in the Schreiber study.
Based on these findings, I hypothesized that the lack of a strong neo-antigen
distinguishes PDA from MCA-driven tumors and from tumors responsive to
immunotherapy, and may be more critical than an immunosuppressive microenvironment
in determining rejection. I therefore predicted that introducing a strong neo-antigen into
the same model of PDA would prompt a T cell-dependent response and reproduce key
findings from the MCA-driven model.

RESULTS
In lieu of an endogenous neo-antigen, I chose to introduce a known epitope to our
non-immunogenic 4662 line that would mimic the activity of a mutation-derived antigen.
In particular, ovalbumin (OVA) protein includes a well-established immunodominant
peptide (SIINFEKL) that binds with high affinity to H2-Kb and therefore mimics
immunological properties of a tumor neo-epitope (Rotzschke et al., 1991). I therefore
retrovirally transduced 4662 PDA cells with an OVA-expressing construct (Wang et al.,
2008) labeled with a Td-Tomato marker to create PDA cells that express full-length OVA
for processing and presentation by H2-Kb MHC class I alleles (Fig 18A).
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Cells were sorted post-transduction for expression of Td-Tomato, and a representative
clone (V6.Ova) was selected for further studies (Fig. 18B). V6.Ova cells were found to
effectively process and present SIINFEKL on H2-Kb, based on reactivity with a
fluorochrome-labeled mAb specific for the peptide-MHC complex (Fig. 18B). Baseline
expression of MHC class I was similar in V6.Ova and parental 4662 cell lines, and was
comparably upregulated following stimulation with IFNγ; in contrast, MHC class II was not
found to be expressed on either cell line despite treatment with IFNγ (Fig 19). ) Negative
sorting of transduced cells was then used to derive a cell line (“OvaNeg”) to be used as a
control for the three TdT-Ova clones (G10.Ova, G7.Ova, and V6.Ova) (Fig. 20A).
Subcutaneous implantation of V6.Ova cells even at a high dose (106 cells) resulted in
lymphocytic infiltration at day 8, followed by complete tumor rejection; however, depletion of
CD8 T cells prior to implantation permitted rapid outgrowth of V6.Ova tumors (Fig. 21).
Neither administration of αCD4- nor αNK1.1-depleting antibodies prevented tumor rejection
(Fig. 21), suggesting that CD8-dependent immunity was necessary and sufficient for rejection
of V6.Ova cells. I also tested a lower dose of V6.Ova (7.5x105 cells) and likewise observed
poor survival when CD8 cells were depleted, in contrast to 100% cure and long-term survival
of isotype-treated mice implanted with this number of V6.Ova cells (Fig. 22). Similar
findings were observed for two other 4662-derived Ova-expressing clones (Fig. 20B).
To assess whether this anti-tumor response could be recapitulated in the pancreatic
microenvironment, orthotopic implantation and ultrasound monitoring for tumor growth were
performed in syngeneic mice. Parental 4662 grew rapidly in all experiments when implanted
in the pancreas of untreated wild-type mice (Fig. 23A) and recapitulated the histology of
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autochthonous KPC tumors (Fig 23B). In contrast, 14 of 17 immune-competent mice (82%)
tested in multiple independent experiments rejected the same dose of orthotopically implanted
V6.Ova cells (Fig 24A, isotype cohort; Fig. 25A) and achieved long-term survival compared
to the parental 4662 line (Fig. 25B). Antibody-mediated depletion of CD8 T cells abrogated
this effect, such that orthotopically implanted V6.Ova cells grew aggressively (Fig. 24A) and
required euthanasia of mice in all cases (Fig. 24B). Thus, OVA expression by tumor cells is
sufficient to mediate and maintain CD8-dependent tumor rejection in multiple
microenvironments, including the pancreas (Fig. 25C).
Moreover, mice cured of V6.Ova subcutaneous implantation rejected or resisted rechallenge with 4662 parental cells; this effect was lost with CD4/CD8 cell depletion
immediately prior to re-challenge (Fig. 26). These data are consistent with epitope spreading,
whereby T cell immunity can be established against 4662 endogenous antigens in the setting
of a strong, acute inflammatory immune response; in this case, the immune response to OVA
cultivates the evolution of immunity against covert antigens. These data further underscore
that, as previously observed in the setting of chemotherapy and CD40 agonists (Winograd et
al., 2015), PDA tumor cells express otherwise immunologically quiescent endogenous (nonOVA) antigens that are nevertheless capable of mediating T cell-dependent tumor rejection
when provided with the necessary immunological impetus.
Although these findings with the V6.Ova clone recapitulated critical features of the
elimination phase of immunosurveillance, the powerful anti-tumor response may have masked
potential immune escape and thereby truncated the immunoediting process. To allow further
study of the escape phase, V6.Ova cells were mixed with OvaNeg cells at high ratios (90%
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V6.Ova: 10% OvaNeg, and 80% V6.Ova: 20% OvaNeg) for a constant subcutaneous dose of
7.5x105 cells (Fig. 27). Pure populations of both the V6.Ova clone and the OvaNeg cells were
included for comparison, and each cohort was treated with αCD8 antibody or an isotype
control.
Despite exhibiting slower growth compared to parental 4662 or OvaNeg cells, tumors
ultimately emerged from each 90% V6.Ova or 80% V6.Ova isotype implant. In each case,
with CD8-depletion, tumor growth accelerated to the same rate as observed for the pure
population of Ova-negative cells treated with or without CD8 depletion (Fig. 28). Overall
survival was intermediate in the 90% and 80% V6.Ova cohorts compared to either pure
population of cells (Fig. 29). The only cohort to achieve cure and long-term survival was the
CD8-replete cohort implanted with 100% V6.Ova, as I had anticipated (Fig. 28 and Fig. 29).
To understand antigen-specific responses in these experiments, I established tumors
from 80% V6.Ova and control lines for two weeks, at which point complete remission is
achieved in mice administered 100% V6.Ova cells. Peptide-MHC tetramer staining for the
presence of intratumoral Ova-specific CD8+ T cells revealed a 40-fold enrichment of
tetramer-positive cells in the tumors from 80% V6.Ova implants compared to the spleens of
the same mice; these intratumoral Ova-specific CD8+ cells were likewise significantly
enriched compared to tumors from mice implanted with an equivalent dose of parental 4662
cells, or tumors from mice depleted of CD8 T cells, thereby demonstrating a robust adaptive
immune response in vivo (Fig. 30). Tumor-infiltrating Ova-specific CD8+ T cells
prominently expressed granzyme B and Tbet, consistent with an effector phenotype;
moreover, these Ova-specific CD8 T cells were highly functional even after 3 weeks,
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expressing Ki67 and IFNγ upon stimulation ex vivo (Fig. 31). Overall, this effector phenotype
was most prominent in tumor compared to spleen (Fig. 30 and 31). These results suggest a
highly specific CD8 T cell response to Ova-expressing cells that bypasses Ova-negative cells.
However, the rapid kinetics in this experiment did not provide sufficient time for the
development of epitope spreading, which might have otherwise prevented outgrowth of an
Ova-negative tumor (as in Fig. 26).
To determine whether the emerging tumor cells themselves had been sculpted by a
host T cell response, Td-tomato expression was assessed in tumors allowed to establish for
two weeks. Consistent with immunoediting, tumor cells that eventually grew from 80%
V6.Ova implants in isotype-treated mice did not express Td-tomato, resulting in expression
identical to parental 4662 tumors (Fig. 32). Moreover, the stromal architecture of these tumors
resembled that of 4662 parental tumors (Fig. 33). These results are consistent with the escape
and subsequent proliferation of Ova-negative tumor cells from the original mixed implant; the
data also demonstrate that elimination of antigen-rich cells can occur even in the presence of
the immunosuppressive microenvironment orchestrated by escaping tumor cells. In contrast,
CD8-depleted cohorts challenged with 100% V6.Ova and 80% V6.Ova significantly and
proportionately retained their tumor expression levels of Td-tomato (Fig. 32). Loss of Tdtomato expression in the presence of activated intratumoral CD8+ T cells likely represents
selective outgrowth of the Ova-negative tumor cell subset that escapes T-cell mediated
elimination. Thus, tumor-sculpting effects were mediated by antigen-specific T cells
responding to a neo-antigen, homing to the tumor and executing effector function despite the
presence of a desmoplastic microenvironment.
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DISCUSSION and CONCLUSIONS
This study demonstrates that ectopic expression of a strong neo-antigen in PDA cells fully
rescues the immunoediting and escape phenotype despite an immunosuppressive stroma,
without the need for additional therapeutic interventions. I also showed that a well-developed
primary response against a neo-epitope can instigate epitope spreading to endogenous
antigens and foster a memory response against tumor cells lacking such epitopes. Thus, cancer
immunosurveillance manifests according to the antigenic strength of the tumor, with the
capacity to override tumor microenvironmental regulation. These findings have clinical
implications. First, variable expression of neo-epitopes may explain differences in de novo
and therapy-induced cancer immunity; human melanoma and murine MCA tumors reside at
one end of the spectrum (“hot” tumors) and human and murine pancreatic carcinoma represent
the other extreme (“cold” tumors) (Schumacher and Schreiber, 2015; Sharma and Allison,
2015). Second, tumor rejection on the basis of non-mutated endogenous antigens reaffirms
the biological importance of such antigens and the therapeutic potential – and perhaps
necessity – of vaccines that target them. Overall, this study reconciles seemingly incongruous
manifestations of immunosurveillance across the cancer spectrum by highlighting the
dominant role of antigen strength.
Schreiber recently reviewed the importance of neo-antigens in tumor
immunology, and asserted that these protein-altering mutations (the source of tumorspecific antigens, or TSAs) are the basis of future therapeutics (Gubin et al., 2015). He
attributed a lesser role to tumor-associated antigens (TAAs), because these proteins are
“self” antigens and therefore rely upon aberrant or excessive expression to overcome
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tolerance and induce immune responses. He described a complex pipeline for
personalized immunotherapy based on genomic mining for such neo-antigens, various
algorithms for predicting MHC Class I binding, and subsequent use of peptide pulsing
and tetramer extraction of TILs for adoptive transfer. Although these methods have been
given credence by a variety of studies (Snyder et al., 2014; Carreno et al., 2015; Rizvi et
al., 2015), PDA has proven highly refractory to various immunotherapies, and moreover
lacks a relevant mutational burden that would supply such neo-epitopes. Indeed, simply
introducing a “neo-antigen” brought PDA back to the realm of immune-sensitive cancers
– so robustly that additional checkpoint inhibition was unnecessary. Clearly, neoantigens reign supreme in terms of their potential for initiating robust and durable
immune responses, but those tumors with a dearth of such antigens at baseline will
remain refractory.
I discovered that a “neo-antigen” in the form of ovalbumin can drive a primary
immune response and can induce T cell-mediated protection upon subsequent rechallenge with tumor cells lacking the neo-antigen, presumably on the basis of epitope
spread. This novel finding provides hope for treatment of immunologically “cold”
tumors – a subset that Schreiber does not address in his review. Thus, the importance of
TAAs should not be underestimated in the context of certain cancers like PDA. These
cancers indeed harbor weaker antigens that remain dormant until unveiled in the setting
of a strong primary response. Although OVA may be critiqued as an “irrelevant” peptide
in terms of tumor immunology, its immunogenicity alone appears to provide the key to
unlocking relevant TAAs. This concept might be pertinent in a vaccination setting for
cancers that would otherwise remain immunologically quiescent, and would not rely
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upon personalized therapy and the extensive pipeline described by Schreiber. Epitope
spread and TAAs expand the current armamentarium of immunotherapy against “cold”
tumors.
Another advantage of targeting TAAs is the diminished susceptibility to antigenloss variants, which may ultimately negate the benefit of neo-antigen-based therapies.
Additionally, the T cell-dependent protection generated by epitope spread did not require
additional T cell stimulation in the form of CD40 agonists or checkpoint inhibitors, and
demonstrated efficacy in the presence of an intact CD4+ compartment. The obsolescence
of additional therapies would reduce the risk for auto-immunity and related side effects.
Most importantly, the potential for universal efficacy of this vaccination approach using
any strong antigen demands further investigation.
Ovalbumin can induce central tolerance under circumstances of germline
expression (Gallegos and Bevan, 2004), but further studies could determine if such
tolerance would permit outgrowth of the V6.Ova cells that are invariably rejected when
expressed as a “neo-antigen.” Using transgenic mice that constitutively express
ovalbumin under the actin promoter, outgrowth of a V6.Ova implant would demonstrate
that this antigen can, in fact, be subjected to immune tolerance. This study is currently
ongoing in the laboratory. Additionally, constructs encoding alterations in the
immunodominant SIINFEKL peptide (or class II epitopes) could be introduced to the
parental 4662 cell line to induce variable degrees of immunogenicity, thereby elucidating
the threshold of antigen strength required for immune control. Other documented tumor
antigens – including neo-antigens such as -spectrin, as well as self-antigens like
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Gp100—could be evaluated for an ability to override the immunosuppression of PDA
and induce tumor regressions with similar efficacy to ovalbumin (Bakker et al., 1994;
Kawakami et al., 1994; Matsushita et al., 2012). Thus, ovalbumin has provided a useful
tool for studying the balance between strong antigens and immunosuppression, and will
continue to provide a means of studying the “antigenic threshold” required for anti-tumor
immunity. It would be additionally informative to re-assess these findings using
documented tumor neo-antigens or self-antigens.
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FIGURES
A

B

Fig 18. Tdt-Ova 4662 processes and presents SIINFEKL peptide on MHC class I.
(A) Parental 4662 cells were retrovirally transduced with a Td-Tomato/OVA-expressing
(Tdt-OVA) construct, and sorted to generate single-cell clones. (B) Flow cytometric
analysis of the parental 4662 cell line (top panels) compared to the V6.Ova clone
(bottom panels). Cells were assessed for expression of Td-tomato (left panels),
incubated with or without IFN and stained using a mAb against SIINFEKL-bound H2Kb (MHC class I, right panels), gating on viable (Live/Dead aqua-negative) cells. Data
represent three independent experiments.

79

Fig 19. Expression of MHC class I and class II on 4662 parental and V6.Ova cell
lines. Parental 4662 and V6.Ova cells were analyzed by flow cytometry for expression of
Td-Tomato, MHC class I (H2-Kb and H2-Db) and MHC class II (I-Ab) with or without
IFNγ stimulation in vitro. Positive control for MHC class II staining is shown below for
total wildtype (WT) splenocytes and CD19+ B cells.
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Fig 20. Additional Tdt-Ova expressing 4662 PDA clones. (A) Td-tomato expression
levels of three 4662 Tdt-Ova tumor clones (V6.Ova, G7.Ova and G10.Ova) compared to
4662 parental and OvaNeg (negatively sorted) cell lines, gating on viable (7-AADnegative) cells. (B) Survival data of immune-competent or CD8-depleted C57BL/6 mice
implanted subcutaneously with 0.75x106 cells of the additional G7.Ova and G10.Ova
clones (N=4-5 mice per cohort). P-values were determined by Log-rank (Mantel-Cox)
analysis. One mouse was censored for non-tumor related mortality (CD8-depleted cohort,
G7.Ova clone).
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Fig 21. Subcutaneous rejection of V6.Ova clone is CD8 T cell-dependent. A high
dose of the V6 clone (106 cells) was subcutaneously implanted in syngeneic mice (top)
treated with an isotype control antibody, CD8-depleting antibody (αCD8), CD4-depleting
antibody (αCD4), or an NK cell-depleting antibody (αNK1.1) and monitored for growth
over time by caliper. N=7-8 mice per cohort (P<0.0001 by two-way ANOVA). Below,
H&E of an implant at day 8 of an isotype-treated mouse showing presence of tumor cells
with marked infiltration of lymphocytes (10x, and inset 40x).
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Fig 22. V6.Ova clone is subcutaneously rejected in immune-competent mice,
resulting in long-term survival. Tumor growth at a lower inoculum of 0.75x106 V6.Ova
cells (A) was assessed in isotype-treated and CD8-depleted cohorts, which were also
monitored for overall survival (B). N=12-13 mice per cohort; P-values represents analysis
by two-way ANOVA (tumor growth) and Log-rank/Mantel-Cox test (survival).
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Fig 23. Orthotopic implantation of the 4662 cell line grows out in immunecompetent mice and reproduces classic PDA histology. (A) The parental 4662 cell line
was implanted orthotopically in immune-competent C57BL/6 host mice at a dose of
0.125x106 cells (N=8). Tumor growth was assessed by serial ultrasound and is shown for
each individual mouse post-injection until the time of death. (B) H&E analysis of a
representative 4662 tumor 22 days post-injection (10x).
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Fig 24. Orthotopic rejection of V6.Ova implants and long-term survival of recipient
mice is CD8 T–cell dependent. Growth of V6.Ova tumor cells implanted orthotopically
in mice treated with isotype control or αCD8 with an inoculum of 0.125x106 cells. Mice
were monitored for tumor growth by ultrasound (A) and assessed for overall survival (B).
N=9-10 mice per cohort; data shown are pooled from two independent experiment
experiments. Analysis was performed by two-way ANOVA (tumor growth) and Logrank/Mantel-Cox (overall survival).
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Fig 25. Summary of orthotopic and subcutaneous implant studies. (A) The V6.Ova
clone was orthotopically implanted in untreated immune-competent C57BL/6 mice, and
tumor growth was monitored by ultrasound. (B) Comparison of overall survival for
orthotopic experiments in Fig 23 (4662 parental) and 25A (V6.Ova); P-value calculated
by Log-rank/Mantel-Cox test. (C) A summary of subcutaneous and orthotopic growth of
parental 4662 cells, and isotype-treated or CD8-depleted V6.Ova-implanted cohorts.
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Fig 26. Re-challenge with Parental 4662 results in T cell-dependent tumor
regressions and delayed tumor outgrowth. C57BL/6 mice that rejected a subcutaneous
V6.Ova implant after six weeks were either CD4/CD8-depleted or administered an
isotype control, and then re-challenged with parental 4662 on the opposite flank. A third,
naïve cohort was simultaneously challenged with parental 4662 at the same dose of 105
cells. N=9-10 mice per cohort. Mice were followed by caliper for tumor growth and
monitored for overall survival. P-values represent analysis by two-way ANOVA or Logrank/Mantel-Cox tests, respectively. ** represents P<0.01 and *** represents P<0.001.
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Fig. 27 Experimental design of competition assay between V6.Ova cells and
negatively sorted (OvaNeg) cells. Ova+ and Ova– 4662 cells were implanted
subcutaneously at various ratios in immune-competent or CD8-depleted cohorts as shown
(N=5 mice per cohort) and monitored for tumor growth and overall survival.
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Fig 28. Mixed implants of V6.Ova and OvaNeg cells grow in immune-competent
recipients with kinetics proportional to the admixture ratio. Subcutaneous implants
containing either a combination of Ova+ and Ova- cells (90% V6.Ova and 80% V6.Ova)
or a homogenous population of V6.Ova or OvaNeg cells were assessed for tumor growth.
Data are shown as the individual growth curves for each mouse per cohort; P-values
represent two-way ANOVA.
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Fig 29. Survival of mice implanted with mixtures of V6.Ova and OvaNeg cells is
dependent upon the admixture ratio. Mice implanted with a combination of Ova+ and
Ova- cells (90% V6.Ova and 80% V6.Ova) or a homogenous population of V6.Ova or
OvaNeg cells were assessed for overall survival; P-values were determined by Logrank/Mantel-Cox for each cohort.
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Fig 30. Ova-specific T cells are highly enriched in the tumors of mice implanted with
80% V6.Ova. Tetramer staining of Ova-specific CD8+ T cells in 80% V6.Ova tumors
compared to spleens at day 14 (top), and quantified in the tumor across all cohorts
(bottom). N=5-7 mice per cohort; data are representative of three independent
experiments. *** indicates P<0.001 by unpaired two-tailed Student’s t-test (top), and
**** P<0.0001 by two-way ANOVA (bottom).
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Fig 31. Intratumoral CD8+ T cells in 80% V6.Ova implants are highly functional
and proliferative. The tumor-infiltrating CD8+ T cells in mice implanted with 80%
V6.Ova cells were assessed by flow cytometry for intracellular levels of Granzyme B,
Tbet, and Ki67 at day 21. IFNγ expression was also assessed by stimulation with
PMA/ionomycin. N= 6 mice per cohort. *** indicates P<0.001 by unpaired two-tailed
Student’s t-test (upper graphs) and **** represent P<0.0001 by two-way ANOVA (lower
graph).
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Fig 32. Loss of Td-tomato expression in V6.Ova implants is abrogated by CD8depletion. Tumor-enriched cells (CD45- CD31- CD90-) were assessed for Td-Tomato
expression by flow cytometry; Td-tomato+ cells are shown as a percentage of this tumorenriched population (top graph). N=5-7 mice per cohort. **** indicates P-value<0.0001
calculated by two-way ANOVA. At bottom, representative data are shown as a
histogram of Td-tomato+ cells for each cohort.
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Fig 33. Tumor histology of 80% V6.Ova implants resembles parental 4662 implants.
H&E stain of representative isotype-treated 80% V6.Ova tumor (10x).
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CHAPTER 5 – Discussion and Future Directions

My thesis work has addressed a critical gap in our understanding of immunoediting and
how it manifests in an oncogene-driven cancer model with a known immunosuppressive
microenvironment, compounded by refractoriness to current immunotherapies in the
clinic. PDA is thus set apart from other tumors such as melanoma and non-small cell
lung cancer, in which clinical benefits have been readily demonstrated on the basis of
checkpoint therapy or adoptive T cell transfer (Lennerz et al., 2005; Zhou et al., 2005;
Rizvi et al., 2015). These successes ultimately rely upon the presence of tumor-specific
antigens, especially neo-antigens, which distinguish the tumor from “self” and therefore
are not subject to central tolerance in the developing immune system. Despite the
dominance of neo-antigens in driving anti-tumor immunity, I have shown that the clinical
outcome of surveillance can be manipulated therapeutically regardless of the presence or
absence of classically described immunoediting (Fig. 34).
Re-visiting the immunoediting paradigm
I systematically utilized our KPC mouse model of PDA, which is a GEMM faithful to the
human disease in both its histology and presentation, to reassess the landmark studies
performed by Schreiber and others. I observed that the presence or absence of T cells is
irrelevant to the natural history of PDA in this model, eschewing the fundamental tenet of
tumor immunology that T cells interact with tumors and invariably sculpt their
development. My thorough assessment of the immunoediting hypothesis in the KPC
model has highlighted a number of key differences from the current theory:
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T cell-depleted KPC mice do not demonstrate a decreased median overall survival
compared to their immune-competent counterparts; RAG2-/- mice subjected to
MCA-induced carcinogenesis demonstrate an increase in tumor incidence and a
decrease in median overall survival. Thus, the growth of KPC tumors is
independent of T cell surveillance, whereas MCA-induced tumors are subject to T
cell surveillance.



Tumor cell lines derived from T cell-depleted KPC mice are not susceptible to
immune rejection in immune-competent mice; 40% of MCA-derived tumors
arising in RAG2-/- mice are rejected in immune competent mice. Thus, KPC
tumors do not undergo immunoediting. MCA-induced tumors undergo editing in
immune-competent hosts.



Checkpoint blockade does not induce immunosurveillance and rejection of KPCderived cell lines in immune-competent hosts; the same checkpoint blockade in
MCA progressor cell lines renders them susceptible to antigen-specific T cell
surveillance. Thus, even checkpoint blockade does not elicit surveillance in KPCderived cell lines.



Ectopic expression of a strong “neo-antigen” in an immune-refractory KPC cell
line fully restores immunosurveillance; MCA-derived tumor cell lines naturally
express neo-epitopes such as -spectrin, Lama4, and Alg3 without a need for
ectopic expression to drive surveillance. Thus, the genomic landscape of KPC
tumors and MCA-derived tumors affects the outcome of immunosurveillance.
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T cells therefore appear to be ignorant of the presence of these tumors, suggesting that the
microenvironment pre-empts a T cell response, and/or these tumors are inherently nonantigenic. The immunoediting hypothesis does not address either of these possibilities.
Thus, the theory that tumor outgrowth in immune-competent individuals is predicated
upon tumor escape is not upheld in PDA and likely other cancers of the same ilk (Fig 35).

Microenvironment vs. Immunogenicity in the KPC model
I found that two factors (tumor microenvironment, and presence of neo-epitopes)
ultimately play a role in failed immunosurveillance of murine or human PDA, but that
they are not equally accountable for that failure. Using whole exome sequencing (WES)
of my various PDA cell lines to observe mutations and potential neo-antigens on a
genomic level, I validated that regardless of the immune status of the donor mouse, these
cells lines exhibited few mutations. Moreover, virtually none of these mutations was
predicted to bind strongly to MHC class I in a biologically relevant manner. It therefore
appears that murine PDA is immunologically “quiescent,” a finding substantiated by
human data from the TCGA. According to cytolytic and CD8 signatures from the
publicly available RNA-seq data, PDA is non-responsive in comparison to melanoma and
lung cancers. Thus, both murine and human data indicate that certain tumor subsets are
immunologically “cold”, while others are “hot,” and that the clinical literature mirrors
this finding in terms of responsiveness to current immunotherapies.
Despite the lack of overt immunogenicity in KPC-derived tumors, we determined
that disruption of the microenvironment can lead to anti-tumor responses based on
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weaker, endogenous antigens. Long-term CD4 depletion in the KPC mouse increased
survival, but this benefit was lost upon concurrent ablation of CD8 cells, suggesting a
CD4-mediated tumor microenvironment that restrains an otherwise relevant cytotoxic T
cell response. Although the CD4-depleted mice ultimately succumbed to tumor burden,
some degree of CD8-mediated protection was present in these mice and delayed the time
to tumor onset. In support of this finding, a cocktail of checkpoint inhibitors (CTLA-4
and PD-1) and an immune-stimulatory vaccine (agonistic CD40/gemcitabine/abraxane)
resulted in subcutaneous regressions and CD8-dependent memory responses. Both
studies indicate that disrupting the tumor microenvironment and/or stimulating T cells
can elicit reactions against endogenous antigens.
To determine the degree to which each of these factors contributed to failed
immunosurveillance, I induced expression of a strong antigen to the otherwise nonimmunogenic 4662 cell line. Introduction of Ova in this setting, without TME disruption
or further immune modulation, allowed for an endogenous response that resulted in
complete subcutaneous regressions and nearly universal responses in the pancreas. Thus,
expression of a strong antigen can override the tumor microenvironment without need for
further intervention, suggesting that the microenvironment is not as drastically
immunosuppressive as previously believed. With this single manipulation of the tumor
itself, as proven by competition studies admixing Ova-expressing and parental 4662 cells,
immunosurveillance and immunoediting are fully restored. Thus, the ultimate failure of
surveillance is tumor-intrinsic, with a supporting role by immunosuppressive factors in
the microenvironment.
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Clinical implications
Perhaps the most intriguing finding of my study was that a primary response
against Ova-4662 cells could allow for subsequent protection against re-challenge with
the parental “non-immunogenic” cell line. In this setting, neither immunotherapy nor
strong antigens were required to elicit durable responses or stable disease in the mice.
This finding has the most striking implications for the clinic.

Variable expression of

neo-epitopes may indeed underscore differences in response to immune checkpoint
therapy, for which human melanoma and murine MCA tumors reside at one end of the
spectrum (“hot” tumors) and human and murine pancreatic carcinoma represent the other
extreme (“cold” tumors) (Schumacher and Schreiber, 2015; Sharma and Allison, 2015).
These findings argue a case for sequence-based decisions in predicting efficacy of cancer
immunotherapies. However, the need for such immunotherapies and personalized
medicine may be rendered obsolete with the simple use of a vaccine, hearkening back to
the initial implications of Coley’s toxins (Coley, 1891). In Coley’s studies, a completely
unrelated set of antigens generated by infection with erysipelas allowed for concurrent
regressions of various lymphomas.
Although such findings may seem antiquated, contemporary literature validates
the pursuit of vaccines against cancers of a non-viral etiology. A recent study used the
same KPC model to evaluate the effects of immunization with an attenuated form of
Listeria monocytogenes, which was engineered to express the Kras mutation (Keenan et
al., 2014). Similar to my studies, Keenan et al utilized a completely unrelated but highly
immunogenic bacteria to induce a response that overcomes central tolerance.
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Interestingly, the effect only delayed progression of early stage PanINs, and required
concomitant T-reg depletion. However, the study provides proof of principle that a
vaccine against a non-viral cancer can be efficacious and allows for specific targeting of
any cell expressing mutant Kras, which is present in greater than 95% of PDA patients.
The potential for universal application of such an approach is highly appealing, and
complements Schreiber’s personalized method predicated on neo-antigens.
Another broadly applicable approach re-emerging in the field of tumor
immunology is immunization by whole-tumor lysate (Chiang et al., 2015). This method
can be used with allogeneic or autologous whole tumor cell lysates; the benefit of the
former is the universality, as demonstrated by the use of GVAX against prostate cancer,
but the latter offers greater specificity for an individual’s unique pool of tumor antigens.
Tumor cells can also be genetically modified to secrete GM-CSF and other DC-activating
cytokines to enhance their efficacy. In either case, the process of necrosis (for example,
by freeze-thaw cycles) induces release of HMGBI, heat shock proteins, and other cellular
components from the mitochondria and nucleus that induce an inflammatory response
(Sauter et al., 2000). Interaction of dendritic cells with these cellular components via
TLR-4 induces their maturation and allows for presentation of local antigens at the site of
vaccination. Moreover, dead tumor cells do not secrete the classical immunosuppressive
factors previously described (see introduction).
Here, the re-challenge data (Fig. 26) suggest that a vaccine-like effect may have
occurred during the primary anti-Ova4662 response. Necrosis induced by cytolytic Ovaspecific T cells likely released endogenous antigens in an immunostimulatory setting,
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permitting the epitope spread effect observed upon re-challenge. To verify this effect,
C57BL/6 mice could be immunized with V6.Ova lysate and re-challenge with parental
4662 to see if the same protective effect is observed.
Future studies might include vaccination of juvenile KPC mice with tumor lysate
from the V6.Ova cell line, followed by monitoring of tumor incidence and overall
survival compared to a control cohort receiving a sham vaccine. Although I previously
attempted to use a freeze-thaw lysate of parental 4662 cells to induce regression in
spontaneous KPC tumors, CD8+ T cells were unable to traffic into the tumor even in
combination with gem/CD40 therapy (Fig. 36); only CD4+ cells achieved infiltration,
and no regressions were observed (Beatty et al., 2015). Vaccination with a lysate of Ovaexpressing 4662 might prompt a robust enough primary CD8+ response to permit full T
cell trafficking to the autochthonous tumor microenvironment. If effective, this
technique would represent an allogeneic whole tumor vaccine, reliant upon the presence
of shared antigens between 4662 and other KPC-derived tumors. The vaccine effect
could be further boosted with TLR-agonists like LPS or a CD4-depleting therapy to
reduce immunosuppression in the developing tumor microenvironment. Various
combinations of these approaches may yield a highly effective prophylactic vaccine
against pancreatic cancer in the KPC mouse model, which would have significant clinical
implications. A tumor vaccine would allow for the benefits of immunosurveillance by
undermining tumor development at inception, thereby obviating the escape phase of
immunoediting and minimizing treatment-related toxicities – the current limiting factors
of immunotherapy as a whole.
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Fig 34. Revised model of tumor immunosurveillance. Updated schematic of tumor
surveillance, demonstrating divergent host-immune interactions based on expression of
neo-antigens, as well as potential therapeutic interventions for both immunologically
“hot” and “cold” tumor subtypes.

102

A

B

Fig 35. Comparison of Immunoediting in MCA and KPC models of tumorigenesis.
(A) Subcutaneous growth of MCA (black) or KPC (red) cell lines derived from immunecompetent or immune-compromised mice upon implantation in immune-competent or
immune-compromised recipients. Right panel, growth of MCA or KPC cell lines in the
context of checkpoint inhibitors. (B) Subcutaneous growth of antigen-expressing MCA
or KPC cell lines in immune-competent or immune-compromised recipients.
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Fig 36. 4662 Tumor lysate fails to induce a vaccine effect in tumor-bearing KPC
mice. (A) Quantification of immunohistochemistry for CD3+ cells in KPC pancreatic
tumors 14 days post-treatment (n = 4 per group). Data shown as box and whisker plots.
(B) Quantification of immunohistochemistry for intratumoral T cell subsets in the triple
therapy cohort. (C) Representative staining for each intratumoral T cell subset in
pancreatic tumors of KPC mice receiving the triple therapy.
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